presentation slides for covid 19

Unsupported browser

This site was designed for modern browsers and tested with Internet Explorer version 10 and later.

It may not look or work correctly on your browser.

15 Best Free Covid Coronavirus & Virus PowerPoint PPT Templates 2024

Whether you need to make a Covid-related or any other medical presentation, one thing is certain. It’s much faster to start with a coronavirus PowerPoint template than trying to do it from scratch. 

Luckily, there are plenty of free and premium Covid and virus-themed PPT templates available online that you can use as a starting point. 

The Best Source for COVID Coronavirus and Virus PowerPoint Templates (With Unlimited Use)

Envato Elements is the best place to find premium coronavirus, Covid, and virus PowerPoint templates with professional designs. Envato Elements is a subscription-based marketplace. It gives you access to thousands of creative assets — for a single monthly fee:

• premium PowerPoint templates for all your presentation needs
• stock photos and royalty-free music that you can use in your presentations
• fonts, icons, and more to customize your presentation

Explore Virus PowerPoint Templates Now

Envato Elements gives you the best bang for your buck if you need PowerPoint templates and other design assets regularly. Unlike our premium templates, free PowerPoint designs often lack features and customization options.

Top 5 Premium Covid and Coronavirus PowerPoint Templates From Envato Elements for 2024

Before we show you the best free PowerPoint templates with virus themes, here are the top premium coronavirus PowerPoint templates from Envato Elements:

1. Delta Corona Virus PowerPoint Template

First, we've got the Delta Corona Virus PowerPoint template with a modern and clean design. This Covid slides template features 80+ slides. They've got all the necessary content ideas for you to create an engaging presentation.

The template also comes with handmade infographic elements. It was designed in HD resolution and comes in dark and light versions.

2. Covid-19 Virus - Medical PowerPoint Template

The Covid-19 is a medical PowerPoint template with more than 70 unique and modern slides. This Covid presentation template has a gorgeous duotone color scheme, but you can easily customize it to match your brand. You’ll also find unique mockup devices, image placeholders, infographic elements, and more. The template comes in widescreen resolution. 

3. Covirus - Disease & Virus PowerPoint Template

Here’s a unique and trendy Covid and virus PowerPoint template that'll make creating your presentation a breeze. The template comes with 33 unique slides. You can customize colors, fonts, and even the slide layout to create the perfect presentation. You’ll also find image and media placeholders, vector-based icons, and mockup devices. 

4. Secure Virus 19 Medical PowerPoint Template

This coronavirus PPT has twenty-five unique slides. It can help you deliver a comprehensive presentation. Finding the right color scheme for your business won't be a problem. Included are over ninety color schemes that are fully customizable.

You'll find much-needed infographics, vectors, and charts as well. Download this complete Covid PowerPoint template.

5. Covid Virus - Medical PowerPoint Template

This Covid presentation template gives you the power to create an eye-catching presentation. Included are forty-six slides that feature modern designs. Many graphics are included to help you deliver a compelling presentation to your audience. Free web fonts are included, and you can drag and drop in images of your choice to any slide.

The premium templates mentioned are some of the highest quality available. If you're on a budget, you may not be able to afford the premium templates. In this next section, we'll go over the top free PowerPoint templates virus. 

15 Top Free Covid Coronavirus & Virus PowerPoint Templates to Download

Before looking for a free Covid PowerPoint template on the web, check Envato's free offerings first. Try out various premium template files (not always PowerPoint files) at no cost to you.

Here's the deal: 

With that in mind, here are the best free coronavirus and virus PowerPoint templates that you can find and download online for your presentation: 

1. Free Social Distance PowerPoint Template

With the help of this coronavirus PowerPoint template for free, you’ll have no problem explaining social distancing rules. The Covid PowerPoint template includes four pre-designed slides.

2. Medicine Health Care PowerPoint Templates

Try this medicine and healthcare PowerPoint template if you’re looking for a modern template. Use it to present all the necessary information about Coronavirus or any other medical emergency.

3. Medical Laboratory PowerPoint Templates

Here’s a free template virus that would be perfect for any type of virus research presentation. The template comes with individual slides as well as section covers. It includes 25 slides.

4. Coronavirus Pandemic PowerPoint Templates

Share important findings and information about Coronavirus or any other virus with this modern template. It comes with three master slides that you can customize.

5. Covid-19 Coronavirus PowerPoint Templates  

This free Covid PowerPoint template has a dark green background with virus icons. Use it to quickly create a presentation. The template comes with three master slides designed in several resolutions.

6. Infection PowerPoint Templates

Use this fun infection PowerPoint template to create a presentation about virus research or to provide more information about a specific virus. The Coronavirus PPT includes three master slides that you can duplicate to create your presentation.

7. Free COVID-19 Vaccine PowerPoint Template

With the help of this free PowerPoint template with a virus theme, you can easily share all the information people need to know about Covid-19 vaccines. The Covid vaccine theme PowerPoint comes with four slides.

8. Free COVID-19 Presentation Template

Use this Covid presentation template to create a presentation that shares information about the virus and how to fight it. The template has four master slides that you can copy as many times as you need.

9. Free Covid PowerPoint Template

Here’s a minimal and simple COVID PowerPoint template. It features an image that shows the virus spreading all over the world. It also contains four master Covid PowerPoint slides that you can copy for your presentation. 

10. Free COVID PowerPoint Background

Consider this free COVID PowerPoint background for your presentation. It features an image of a word game spelling out coronavirus, pandemic, and virus. 

11. Medical Illustrated. Free PowerPoint Template & Google Slides Theme

Here’s another minimal and clean PowerPoint template. Use it for any type of medical presentation. The Covid presentation template comes with 25 slides.

12. Blue Medical. Free PowerPoint Template & Google Slides Theme

The blue color in this medical and virus PowerPoint template conveys professionalism. It comes with 25 covid PowerPoint slides.

13. Medical Virus. Free PowerPoint Template & Google Slides Theme

This coronavirus PowerPoint template for free can be used for sharing information about the virus and how to prevent the spread. The template comes with 25 slides that you can duplicate, re-order, and delete as you see fit.

14. Free COVID-19 Health System Capacity Curve PowerPoint

Use this free Covid-19 PowerPoint template to showcase the virus's effect on the health system capacity. The template includes several different slide variations.

15. Coronavirus PowerPoint Template

Use this coronavirus PowerPoint template for free to create informative presentations about coronavirus measures, treatments, and protection. It comes with several slides, including section cover and agenda slides. 

How to Make a Coronavirus Presentation in PowerPoint

1. Choose the Right Slides

Not all the slides in the template will work for your presentation. Go through each slide and pick the ones that pertain to your presentation. For the slides, you don't want to use, left-click the slide and choose Delete Slide .

2. Add In Your Content

Now it's time to add in your presentation's content. Have a document open with all the text you want to use for each slide. Then copy and paste the text to each slide.

Each slide has text placeholders. Double-click the placeholder text and select all the text. You can then paste in your text.

3. Add In Your Images

Next, we'll add in our images to make the presentation more visually appealing. Just like the text, there are also image placeholders. To add in your images, click the image icon on each slide. Your computer files pop up. Choose the image you want to add. 

4. Add in Animations

To help add professional polish to your presentation, we'll add in animations. Choose the top menu header that says Animations . From there, choose the animation that you want to have on your slides. To see what each animation looks like, choose the Preview button on the far left side of the menu.

5. Proofread Your Presentation

Often this step is skipped. We get caught up in making our design look perfect and forget to proofread our presentation. Having grammatical errors and misspelled words is the quickest way to make your presentation look unprofessional. Take the time to go over every slide in your presentation before calling it done.

5 Quick Tips To Make Virus-Themed PPT Presentations in 2024

You’ve just seen the best free and premium coronavirus slideshow templates. Now, here are a few quarantine PowerPoint ideas that'll help you design a standout presentation: 

1. Stand Out With Custom Icons and Illustrations

Custom icons and illustrations make your presentation more memorable. Not to mention, they'll make your presentation stand out. The Covid-19 PowerPoint template features modern custom vector graphics that you can use as inspiration.

2. Keep the Text to a Minimum

Don’t overwhelm your audience by adding a lot of text on your slides. This can cause them to read the slide before you’re done presenting it and they may become disengaged. Instead, keep the text to a minimum of one to three bullet points per slide.

3. Use a Professional Color Scheme

You don’t have to shy away from color in your presentation. Make sure that your color scheme is professional and doesn’t contain any clashing colors. You can draw inspiration from this modern Coronavirus Medical PowerPoint template from Envato Elements.

4. Use Charts for Complex Data and Statistics

If you've got a lot of complex data and statistics, consider using charts and infographic elements to represent them. This will make it easier for your audience to understand and absorb the information.

5. Customize the Slides With Your Photos

Using stock photos is a great way to make your presentation more memorable. But you can achieve an even better effect by including photos of you, your team, and your employees. A template like the Corona Virus PowerPoint Template has plenty of image placeholders for you to use.

Discover More Top PowerPoint Template Designs

If you want to see even more PowerPoint template examples or if you need to create a different type of presentation, look at the following template roundups:

Common PowerPoint Questions Answered (FAQ)

If you're creating a Coronavirus PPT presentation and you're not familiar with PowerPoint, you may have some questions. We've got you covered! Here are some common PowerPoint questions and their answers:

1. I'm New to PowerPoint, What Should I Know?

PowerPoint is a powerhouse presentation software. But learning just the basics of the software enables you to create a complete presentation. Check out our ultimate PowerPoint guide to learn these basics.

2. How Should I Design My Slides?

The visual hierarchy of the slides dictates the design. The arrangement of the elements on your page and how they're placed has the biggest effect on what your audience remembers. Your slide's colors, typography, and images used are major contributors to the design of your slides. 

3. Can I Collaborate on One Presentation?

PowerPoint Online makes collaboration possible. This makes it easy to delegate separate tasks that need to be completed for the presentation. For an in-depth guide on how to collaborate as a team, view the article below.

4. What Colors Should I Use In My Coronavirus PPT?

The colors that work well are blue and red. Red helps highlight the urgency and danger of the virus and blue helps build trust with your audience. If your business has a set of brand colors, then you can use these colors as well. 

5. Can I Print Out My Slides?

Yes, you can! Print out your slides may be necessary depending on where you're presenting. Check out the tutorial below for a complete guide on how to print out your slides.

Learn More About Making Great PowerPoint Presentations in 2024

The tips we shared above are only a small selection of what makes a great presentation. If you want to learn more about designing and writing great PowerPoint presentations , check out the tutorials below: 

Create a Coronavirus Presentation Quickly With Templates

If you need to create a presentation about Coronavirus or any other type of medical presentation, there's no shortage of free PowerPoint templates with a virus theme to choose from. But, if you want to make your presentation look more unique, don’t forget to check out premium templates. 

Stop by Envato Elements if you know you’ll be needing PowerPoint templates and other creative assets on the regular or if you've got multiple brands to promote. 

Editorial Note: This post has been updated with contributions from Daniel Strongin . Daniel is a freelance instructor for Envato Tuts+.

Got any suggestions?

We want to hear from you! Send us a message and help improve Slidesgo

Top searches

Trending searches

6 templates

indigenous canada

9 templates

121 templates

education technology

232 templates

39 templates

29 templates

COVID-19 Infographics

It seems that you like this template, premium google slides theme, powerpoint template, and canva presentation template.

COVID-19 has been around for a year now, so it's likely that people would need to provide some statistics about its evolution. For that, you'll need charts, infographics... and that's what you'll find in this template! The slides feature backgrounds with gradients and many layouts contain editable graphs. You can try integrating these designs into our COVID-19 presentation template, as both have been devised to work well together. This is the vaccine against boring slideshows!

Features of these infographics

• 100% editable and easy to modify
• 31 different infographics to boost your presentations
• Include icons and Flaticon’s extension for further customization
• Designed to be used in Google Slides, Canva, and Microsoft PowerPoint and Keynote
• 16:9 widescreen format suitable for all types of screens
• Include information about how to edit and customize your infographics
• Supplemental infographics for the template COVID-19

How can I use the infographics?

What are the benefits of having a Premium account?

What Premium plans do you have?

What can I do to have unlimited downloads?

Combines with:

This template can be combined with this other one to create the perfect presentation:

Don’t want to attribute Slidesgo?

Gain access to over 27300 templates & presentations with premium from 1.67€/month.

Are you already Premium? Log in

Related posts on our blog

How to Add, Duplicate, Move, Delete or Hide Slides in Google Slides

How to Change Layouts in PowerPoint

How to Change the Slide Size in Google Slides

Related presentations.

Premium template

Unlock this template and gain unlimited access

Related Resources

Sonya’s Story (COVID-19)

A daughter prays that her mother’s death helps others understand the dangers of COVID-19

Contagious Chronicles: Don’t Be A Dreaded Spreader

In this episode, NFID experts offer insights on updated recommendations from the Centers for Disease Control and Prevention (CDC) to help prevent the spread of respiratory viruses, including COVID-19, influenza (flu), and respiratory syncytial virus (RSV)

Contagious Chronicles: Updates on COVID-19, RSV, and More

In the inaugural episode, NFID experts discuss new COVID-19 vaccine recommendations for older adults and other updates from the February 2024 meeting of the Advisory Committee on Immunization Practices (ACIP) …

Official websites use .gov

A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS

A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

COVID-19 Overview and Infection Prevention and Control Priorities in non-U.S. Healthcare Settings

Summary of changes: itf ipc covid-19 overview and infection prevention and control priorities in non-u.s. healthcare settings webpage.

• Updated transmission section to reflect CDC guidance
• Added information on certain activities that can increase risk of COVID-19 infection with references to ventilation guidance by CDC and WHO
• Updated and re-arranged list of symptoms on webpage to reflect current CDC guidance
• Removed section on Illness Severity
• Amended information and references in People at Higher Risk for Severe Illness, noting that these people should be prioritized for vaccination
• Revised COVID-19 Preventative actions section to reflect vaccination, masks, and additional preventative actions that should be continued
• Added additional references to preventative actions section
• Removed treatment section
• Added information on IPC in the context of vaccination delivery
• Revised list of Aerosol Generating Procedures based on updated guidance from WHO and updated references
• COVID-19 Background

Transmission

• People at Higher Risk
• Prevention and Treatment
• What is IPC?

COVID-19 Overview and Infection Prevention and Control Priorities in non-US Healthcare Settings [PPT – 5 MB]

This overview was created for healthcare workers in non-U.S. healthcare settings and government officials at ministries of health working on the Coronavirus Disease 2019 (COVID-19) response.

The information in this document draws from the Centers for Disease Control and Prevention (CDC) and World Health Organization (WHO) guidance documents and Infection Prevention and Control (IPC) priorities for the response to COVID-19 in healthcare settings and includes information that can be used in non-U.S. contexts.

Structure of the document

This overview is organized by first presenting a background on coronaviruses. It then briefly describes the emergence, transmission, symptoms, prevention, and treatment of COVID-19. The rest of the document reviews COVID-19 IPC priorities, in non-U.S. healthcare settings.

Coronavirus Background:

Coronaviruses are a large family of viruses that can cause illness in animals or humans. In humans there are several known coronaviruses that cause respiratory infections. These coronaviruses range from the common cold to more severe diseases such as severe acute respiratory syndrome (SARS), Middle East respiratory syndrome (MERS), and COVID-19.

Coronavirus Disease 2019:

COVID-19 was identified in Wuhan, China in December 2019. COVID-19 is caused by the virus severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), a new virus in humans causing respiratory illness which can be spread from person-to-person. Early in the outbreak, many patients were reported to have a link to a large seafood and live animal market; however, later cases with no link to the market confirmed person-to-person transmission of the disease. Additionally, travel-related exportation of cases occurred.

There are three main ways that COVID-19 can spread:

• By breathing in air carrying droplets or aerosol particles that contain the SARS-CoV-2 virus when close to an infected person or in poorly ventilated spaces with infected persons
• By having droplets and particles that contain the SARS-CoV-2 virus land on the eyes, nose, or mouth – especially through splashes and sprays like a cough or sneeze
• By touching the eyes, nose, or mouth with hands that have the SARS-CoV-2 virus particles on them

The droplets that contain the SARS-CoV-2 virus are released when someone with COVID-19 sneezes, coughs, or talks. Infectious droplets can land in the mouths or noses of people who are nearby or possibly be inhaled into the lungs. A physical distance of at least 1 meter (3 ft) between persons is recommended by the WHO to avoid infection, 1 whereas CDC recommends maintaining a physical distance of at least 1.8 meters (6ft) between persons. Respiratory droplets can land on hands, objects, or surfaces around the person when they cough or talk, and people can then become infected with COVID-19 from touching hands, objects or surfaces with droplets and then touching their eyes, nose, or mouth. Additionally, transmission can occur from those with mild symptoms or from those who do not feel ill.

There are certain circumstances that can increase the risk of infection for COVID-19 such as poorly ventilated space. In indoor spaces with poor ventilation, the concentration of virus particles is often higher than outdoors. 2,3 Other factors that are associated with increased COVID-19 risk include prolonged exposure to those infected with COVID-19, close contact with infected persons, and any other activity that leads to exposure to a greater amount of respiratory droplets and particles.

A wide range of symptoms for COVID-19 have been reported. 4 These symptoms include:

• Fever or chills
• Muscle or body aches
• Sore throat
• Nasal congestion or runny nose
• Shortness of breath or difficulty breathing
• Loss of smell or taste

The estimated incubation period is between 2 and 14 days with a median of 5 days. It is important to note that some people become infected and do not develop any symptoms or feel ill.

People at Higher Risk for Severe Illness

COVID-19 is a relatively new disease; therefore, additional risk factors for severe COVID-19 may continue to be identified. In some cases, people who get COVID-19 can develop severe complications, including difficulty breathing, causing a need for hospitalization and intensive care. 5 These severe complications often lead to death. The risk of severe disease increases steadily as people age. Additionally, those of all ages with underlying medical conditions , including but not limited to heart disease, diabetes or lung disease, are  at higher risk to develop severe COVID-19 compared to those without these conditions. 5 Those at higher risk for severe illness should be prioritized for vaccination. 6

COVID-19 Preventative Actions

COVID-19 can be prevented through pharmaceutical (i.e., vaccination) and non-pharmaceutical interventions (e.g., masking, physical distancing, hand hygiene). All of these preventative measures are important to protect individuals from acquiring and transmitting the SARS-CoV-2 virus and should be done in conjunction with one another.

Vaccination

Getting vaccinated is a preventative measure that people can take to avoid getting sick with COVID-19 and to avoid infecting others. While safe and effective vaccines are a great tool for prevention, it is important to continue other preventative actions such as wearing masks, performing hand hygiene, physically distancing from others, and avoiding crowded spaces and spaces with poor ventilation. 7  There are several vaccine candidates, and many have been listed under WHO’s emergency use.

Wearing masks is another important preventative action for COVID-19 that should continue to be performed. When selecting a mask, there are many factors to consider. 8 Masks should

• Have two or more layers of washable, breathable fabric
• Completely cover the nose and mouth
• Fit snug against the sides of the face and not have gaps
• Have a nose wire to prevent air from leaking out of the top of the mask

It is also important to choose and wear the proper type of mask based on your setting. For example, in a community setting, cloth masks should be worn, whereas during aerosol generating procedures in a healthcare setting, should be worn.

Other preventative actions

Even with the introduction of vaccinations as a tool for prevention against COVID-19 and the proper use of masks, CDC recommends the following key COVID-19 preventative activities: 7 — avoiding crowded spaces or spaces that have poor ventilation or wear a mask in these spaces; performing proper hand hygiene; keeping high touch surfaces clean; monitoring symptoms; and getting tested if ill.

IPC for COVID-19

Infection prevention and control (IPC) is the practice of preventing or stopping the spread of infections from the delivery of healthcare services in facilities like hospitals, outpatient clinics, dialysis centers, long-term care facilities, or traditional practitioners. IPC is a critical part of health system strengthening and must be a priority to protect patients and healthcare workers. In the context of COVID-19, the IPC goal is to support the maintenance of essential healthcare services by containing and preventing COVID-19 transmission within healthcare facilities to keep patients and healthcare workers healthy and safe.

COVID-19 IPC Priorities

• Rapid identification of suspect cases
• Screening/triage at initial healthcare facility encounter and rapid implementation of source control
• Limiting the entry of healthcare workers and/or visitors with suspected or confirmed COVID-19
• Immediate isolation and referral for testing
• Group patients with suspected or confirmed COVID-19 separately
• Test all suspected patients for COVID-19
• Safe clinical management
• Immediate identification of inpatients and healthcare workers with suspected COVID-19
• Adherence to IPC practices
• Appropriate use of personal protective equipment (PPE)
• Unvaccinated healthcare workers, patients, and visitors should be offered resources and counseled about the importance of vaccination.

COVID-19 IPC in the context of vaccination delivery

As safe and effective COVID-19 vaccines continue to be delivered, there are certain recommendations and principles that should be implemented and considered for vaccine administration. Consultations and consensus between WHO, the United Nations Children’s Fund (UNICEF), and the ad hoc WHO COVID-19 IPC Guidance Development Group have led to the development of a document that outlines key IPC principles and recommended proper precautions for safe administration of COVID-19 vaccines. Consult the Infection prevention and control (IPC) principles and procedures for COVID-19 vaccination activities  document when preparing for vaccine deployment. 10

The key IPC principles for COVID-19 vaccine deployment set out in the document include:

• Applying standard precautions during any vaccination activity
• Performing additional IPC precautions like mask use in the context of the COVID-19 pandemic
• Providing healthcare workers with specific training and providing the public with targeted information regarding IPC measures for safe vaccine delivery
• Having a clean, hygienic, and well-ventilated environment with appropriate waste management, and adequate spaces that facilitate best IPC practices like physical distancing
• Ensuring consultation and adherence to national guidance and protocols for IPC measures, including those related to COVID-19

Standard and Transmission-Based Precautions

Standard precautions are a set of practices that apply to the care of patients in all healthcare settings at all times. Standard precautions remain the cornerstone of infection prevention and control. Application of these precautions depends on the nature of the healthcare worker-patient interaction and the anticipated exposure to a known infectious agent. Standard precautions include:

• Hand hygiene
• Personal protective equipment
• Respiratory hygiene and cough etiquette
• Cleaning and disinfection of devices and environmental surfaces
• Safe injection practices
• Medication storage and handling

Transmission-based precautions are a set of practices specific for patients with known or suspected infectious agents that require additional control measures to prevent transmission. These precautions are used in addition to standard precautions.

COVID-19 Transmission-Based Precautions:

Current WHO guidance for healthcare workers caring for suspected or confirmed COVID-19 patients recommends the use of contact and droplet precautions in addition to standard precautions unless an aerosol generated procedure is being performed, in which case airborne precautions are needed. 1 Disposable or dedicated patient care equipment, such as stethoscopes, blood pressure cuffs, should be used. If equipment needs to be shared among patients, it should be cleaned and disinfected between use for each patient using products containing ethyl alcohol of at least 70%.

Also, adequately ventilated single rooms or wards are suggested. For general ward rooms with natural ventilation, adequate ventilation for COVID-19 patients is considered to be 60 L/s per patient. When single rooms are not available, suspected COVID-19 patients should be grouped together with beds at least 1 meter (3ft) apart based on WHO’s recommendations, although some member states, including the United States, have recommended maintaining greater distances whenever possible. COVID-19 isolation rooms or wards should have dedicated bathrooms, which should be cleaned and disinfected at least twice daily.

Additionally, healthcare facilities can also consider designating healthcare workers to care for patients with COVID-19 and restricting the number of visitors allowed in the facility.

Transportation of patients with COVID-19 should be avoided unless medically necessary. If transportation is deemed medically necessary, a mask should be placed on the suspected or confirmed COVID-19 patient. Healthcare workers should also wear the appropriate PPE when transporting patients.

COVID-19 PPE

Contact and droplet precaution PPE are recommended for healthcare workers before entering the room of suspected or confirmed COVID-19 patients. Healthcare workers should be trained on the correct use of PPE, including how to put it on and remove it. Extended use and re-use of certain PPE items such as masks and gowns can be considered when there are supply shortages. Healthcare workers should:

• Use a medical mask (at least a surgical/medical mask)
• Wear eye protection (goggles) or facial protection (face shield)
• Wear a clean, non-sterile, long-sleeve gown

There is a higher risk of self-contamination when removing PPE. Please see instructions for putting on and removing PPE [2.9 MB, 3 pages]  for guidance.

For healthcare workers performing any of the following aerosol generating procedures on patients with COVID-19, it is recommended that a fitted respirator mask (surgical N95 respirators, FFP2 or equivalent) is used as opposed to surgical/medical masks. In addition to wearing a fitted respirator mask, healthcare workers should also wear appropriate PPE, including gloves, a gown and eye protection.

Although there is a difference in determination on which procedures generate infectious aerosol, the current WHO list of Aerosol Generating Procedures includes: 1

• Endotracheal intubation
• Bronchoscopy
• Non-invasive ventilation
• Tracheotomy
• Manual ventilation before intubation
• Cardiopulmonary resuscitation
• Sputum induction
• Dentistry and autopsy procedures

Infection Prevention and Control Resources for COVID-19 in non-U.S. Healthcare Settings:

• Strategic Priority IPC Activities for Containment and Prevention
• Identification of Healthcare Workers and Inpatients with Suspected COVID-19
• WHO. Infection prevention and control during health care when novel coronavirus disease (COVID-19) is suspected or confirmed .29 June 2020.
• Kai-Wang To, K., Tak-Yin Tsang, O., Chik-Yan Yip, C., Chan, KH., Wu, TC., Man-Chun Chan, J…Yuen, KY. Consistent detection of 2019 novel coronavirus in saliva . Clinical Infectious Diseases . 12 February 2020. ciaa149.
• WHO. Transmission of SARS-CoV-2: implications for infection prevention precautions . 9 July 2020.
• WHO. Clinical management of severe acute respiratory infection when COVID-19 is suspected . 13 March 2020.
• The Novel Coronavirus Pneumonia Emergency Response Epidemiology Team. The epidemiological characteristics of an outbreak of 2019 novel coronavirus diseases (COVID-19) – China 2020 . CDCweekly . 17 February 2020. 10.46234/ccdcw2020.032
• Stokes EK, Zambrano LD, Anderson KN, et al. Coronavirus Disease 2019 Case Surveillance — United States, January 22–May 30, 2020. MMWR Morb Mortal Wkly Rep 2020;69:759–765. DOI: http://dx.doi.org/10.15585/mmwr.mm6924e2
• Chen, J., Lu, H., Melino, G. et al. COVID-19 infection: the China and Italy perspectives. Cell Death Dis 11, 438 (2020). https://doi.org/10.1038/s41419-020-2603-0
• WHO. Advise on the use of masks in the context of COVID-19 . 5 June 2020.

To receive email updates about COVID-19, enter your email address:

Exit Notification / Disclaimer Policy

• The Centers for Disease Control and Prevention (CDC) cannot attest to the accuracy of a non-federal website.
• Linking to a non-federal website does not constitute an endorsement by CDC or any of its employees of the sponsors or the information and products presented on the website.
• You will be subject to the destination website's privacy policy when you follow the link.
• CDC is not responsible for Section 508 compliance (accessibility) on other federal or private website.

Coronavirus Disease 2019 (COVID-19) Clinical Presentation

• Author: David J Cennimo, MD, FAAP, FACP, FIDSA, AAHIVS; Chief Editor: Michael Stuart Bronze, MD  more...
• Sections Coronavirus Disease 2019 (COVID-19)
• Practice Essentials
• Route of Transmission
• Epidemiology
• Physical Examination
• Complications
• Approach Considerations
• Laboratory Studies
• CT Scanning
• Chest Radiography
• Medical Care
• Antiviral Agents
• Immunomodulators and Other Investigational Therapies
• Investigational Antibody-Directed Therapies
• Antithrombotics
• Renin Angiotensin System Blockade and COVID-19
• Diabetes and COVID-19
• Therapies Determined Ineffective
• QT Prolongation with Potential COVID-19 Pharmacotherapies
• Investigational Devices
• Guidelines Summary
• CDC Evaluating and Testing Persons Under Investigation (PUI) for COVID-19 Clinical Guidelines
• CDC Sample Collection and Testing Guidelines for COVID-19
• Guidance for Hospitals on Containing Spread of COVID-19
• American Academy of Pediatrics Guidance on Management of Infants Born to Mothers with COVID-19
• NIH Coronavirus Disease 2019 (COVID-19) Treatment Guidelines
• Infectious Diseases Society of America (IDSA) Management Guidelines
• Thromboembolism Prevention and Treatment
• Medication Summary
• Corticosteroids
• Immunomodulators
• Complement Inhibitors
• COVID-19, Monoclonal Antibodies
• Questions & Answers
• Media Gallery

Presentations of COVID-19 range from asymptomatic/mild symptoms to severe illness and mortality. Common symptoms include fever, cough, and shortness of breath. [ 100 ]  Other symptoms, such as malaise and respiratory distress, also have been described. [ 90 ]

Symptoms may develop 2 days to 2 weeks after exposure to the virus. [ 100 ]  A pooled analysis of 181 confirmed cases of COVID-19 outside Wuhan, China, found the mean incubation period was 5.1 days, and that 97.5% of individuals who developed symptoms did so within 11.5 days of infection. [ 101 ]  

Symptom rebound and viral rebound have been described in patients (with or without antiviral treatment). In untreated patients, those (n = 563) receiving placebo in the ACTIV-2/A5401 (Adaptive Platform Treatment Trial for Outpatients with COIVD-19) platform trial recorded 13 symptoms daily between days 1 and 28. Symptom rebound was identified in 26% of participants at a median of 11 days after initial symptom onset. Viral rebound was detected in 31% and high-level viral rebound in 13% of participants. [ 102 ]  

The following symptoms may indicate COVID-19 [ 100 ] :

• Fever or chills
• Shortness of breath or difficulty breathing
• Muscle or body aches
• New loss of taste or smell
• Sore throat
• Congestion or runny nose
• Nausea or vomiting

Other reported symptoms include the following:

• Sputum production
• Respiratory distress
• Neurologic (eg, headache, altered mentality) 

Wu and McGoogan reported that, among 72,314 COVID-19 cases reported to the CCDC, 81% were mild (absent or mild pneumonia), 14% were severe (hypoxia, dyspnea, >50% lung involvement within 24-48 hours), 5% were critical (shock, respiratory failure, multiorgan dysfunction), and 2.3% were fatal. [ 103 ] These general symptom distributions have been reconfirmed across multiple observations. [ 104 , 105 ]

Clinicians evaluating patients with fever and acute respiratory illness should obtain information regarding travel history or exposure to an individual who recently returned from a country or US state experiencing active local transmission. [ 106 ]

Williamson and colleagues, in an analysis of 17 million patients, reaffirmed that severe COVID-19 and mortality was more common in males, older individuals, individuals in poverty, Black persons, and patients with medical conditions such as diabetes and severe asthma, among others. [ 107 ]

A multicenter observational cohort study conducted in Europe found frailty was a greater predictor of mortality than age or comorbidities. [ 108 ]

Type A blood has been suggested as a potential factor that predisposes to severe COVID-19, specifically in terms of increasing the risk for respiratory failure. Blood type O appears to confer a protective effect. [ 109 , 110 ]

Patients with suspected COVID-19 should be reported immediately to infection-control personnel at their healthcare facility and the local or state health department. CDC guidance calls for the patient to be cared for with airborne and contact precautions (including eye shield) in place. [ 22 ] Patient candidates for such reporting include those with fever and symptoms of lower respiratory illness who have travelled from Wuhan City, China, within the preceding 14 days or who have been in contact with an individual under investigation for COVID-19 or a patient with laboratory-confirmed COVID-19 in the preceding 14 days. [ 106 ]

A complete or partial loss of the sense of smell (anosmia) has been reported as a potential history finding in patients eventually diagnosed with COVID-19. [ 20 ] A phone survey of outpatients with mildly symptomatic COVID-19 found that 64.4% (130 of 202) reported any altered sense of smell or taste. [ 111 ] In a European study of 72 patients with PCR results positive for COVID-19, 53 patients (74%) reported reduced olfaction, whereas 50 patients (69%) reported a reduced sense of taste. Forty-nine patients (68%) reported both symptoms. [ 112 ]

Patients who are under investigation for COVID-19 should be evaluated in a private room with the door closed (an airborne infection isolation room is ideal) and asked to wear a surgical mask. All other standard contact and airborne precautions should be observed, and treating healthcare personnel should wear eye protection. [ 22 ]

The most common serious manifestation of COVID-19 upon initial presentation is pneumonia. Fever, cough, dyspnea, and abnormalities on chest imaging are common in these cases. [ 113 , 114 , 115 , 116 ]

Huang and colleagues found that, among patients with pneumonia, 99% had fever, 70% reported fatigue, 59% had dry cough, 40% had anorexia, 35% experienced myalgias, 31% had dyspnea, and 27% had sputum production. [ 113 ]

Complications of COVID-19 include  pneumonia ,  acute respiratory distress syndrome , cardiac injury, arrhythmia,  septic shock , liver dysfunction,  acute kidney injury , and multi-organ failure, among others.

Approximately 5% of patients with COVID-19, and 20% of those hospitalized, experience severe symptoms necessitating intensive care. The common complications among hospitalized patients include pneumonia (75%), ARDS (15%), AKI (9%), and acute liver injury (19%). Cardiac injury has been increasingly noted, including troponin elevation, acute heart failure, dysrhythmias, and myocarditis. Ten percent to 25 percent of hospitalized patients with COVID-19 experience prothrombotic coagulopathy resulting in venous and arterial thromboembolic events. Neurologic manifestations include impaired consciousness and stroke.

ICU case fatality is reported up to 40%. [ 104 ]  

As the COVID-19 pandemic has matured, more patients have reported long-term, post-infection sequelae. Most patients recover fully, but those who do not have reported adverse symptoms such as fatigue, dyspnea, cough, anxiety, depression, inability to focus (ie, “brain fog”), gastrointestinal problems, sleep difficulties, joint pain, and chest pain lasting weeks to months after the acute illness. Long-term studies are underway to understand the nature of these complaints. [ 117 ]  

Post-acute sequelae of SARS-CoV-2 (PASC) infection is the medical term for what is commonly called long COVID or "long haulers". The NIH includes discussion of persistent symptoms or organ dysfunction after acute COVID-19 within guidelines that discuss the clinical spectrum of the disease. [ 118 ]  

The UK National Institute for Health and Care Excellence (NICE) issued guidelines on care of long COVID that define the syndrome as: signs and symptoms that develop during or after an infection consistent with COVID-19, continue for more than 12 weeks, and are not explained by an alternative diagnosis. [ 119 ]  

Please see Long COVID-19 .

Future public health implications

Public health implications for long COVID need to be examined, as reviewed by Datta et al. As with other infections (eg, Lyme disease, syphilis, Ebola), late inflammatory and virologic sequelae may emerge. Accumulation of evidence beyond the acute infection and postacute hyperinflammatory illness is important to evaluate to gain a better understanding of the full spectrum of the disease. [ 120 ]  

Thrombotic manifestations of severe COVID-19 are caused by the ability of SARS-CoV-2 to invade endothelial cells via angiotensin-converting enzyme-2 (ACE-2), which is expressed on the surface of endothelial cells. Subsequent endothelial inflammation, complement activation, thrombin generation, platelet and leukocyte recruitment, and the initiation of innate and adaptive immune responses culminate in immunothrombosis, and can ultimately cause microthrombotic complications (eg, DVT, PE, stroke). [ 121 ]  

Kotecha et al describe patterns of myocardial injury in hospitalized patients with severe COVID-19 who had elevated troponin levels. During convalescence, myocarditis-like injury was observed, with limited extent and minimal functional consequence. However, in a proportion of patients, there was evidence of possible ongoing localized inflammation. Roughly 25% of patients had ischemic heart disease, of which two thirds had no previous history. [ 122 ]  

Reinfection

COVID-19 reinfection is defined as an infected person who has undergone full vaccination, whether they have had a booster or boosters. According to the CDC, reinfection is COVID-19 infection of an individual with 2 different viral strains that occurs at least 45 days apart. It also may occur when an individual has 2 positive CoV-2 RT-PCR tests with negative tests between the 2 positive tests. [ 123 ]

It is essential to determine reinfection rates to establish the effectiveness of current vaccine prophylaxis. Reinfection in vaccinated and non-vaccinated persons probably is due to a variant. [ 123 , 124 ]  

It is important to differentiate reinfection from reactivation or relapse of the virus, which occurs in a clinically recovered person within the first 4 weeks of infection, during which viral RNA testing has remained positive. During relapse, a tiny viral load of dormant virus reactivates, the reason of which often is unclear.

The only way to prove this state is to show that genetic samples taken at the beginning and at the time of reactivation differ genetically; such testing is unusual at the beginning of a person’s illness.

For more information, see COVID-19 Reinfections

CDC. 2019 Novel Coronavirus, Wuhan, China. CDC. Available at https://www.cdc.gov/coronavirus/2019-ncov/about/index.html . Aug. 11, 2022; Accessed: February 20, 2024.

Gallegos A. WHO Declares Public Health Emergency for Novel Coronavirus. Medscape Medical News. Available at https://www.medscape.com/viewarticle/924596 . January 30, 2020; Accessed: February 29, 2024.

Ramzy A, McNeil DG. W.H.O. Declares Global Emergency as Wuhan Coronavirus Spreads. The New York Times. Available at https://nyti.ms/2RER70M . January 30, 2020; Accessed: February 29, 2024.

The New York Times. Coronavirus Live Updates: W.H.O. Declares Pandemic as Number of Infected Countries Grows. The New York Times. Available at https://www.nytimes.com/2020/03/11/world/coronavirus-news.html#link-682e5b06 . March 11, 2020; Accessed: February 29, 2024.

Coronavirus Updates: The Illness Now Has a Name: COVID-19. The New York Times. Available at https://www.nytimes.com/2020/02/11/world/asia/coronavirus-china.html . February 11, 2020; Accessed: February 29, 2024.

WHO Director-General's remarks at the media briefing on 2019-nCoV on 11 February 2020. Available at https://www.who.int/dg/speeches/detail/who-director-general-s-remarks-at-the-media-briefing-on-2019-ncov-on-11-february-2020 . February 11, 2020; Accessed: February 29, 2024.

Gorbalenya AE. Severe acute respiratory syndrome-related coronavirus – The species and its viruses, a statement of the Coronavirus Study Group. Available at https://read.qxmd.com/doi/10.1101/2020.02.07.937862 . February 11, 2020; Accessed: February 29, 2024.

CDC COVID-19 Response Team, Jorden MA, Rudman SL, et al. Evidence for Limited Early Spread of COVID-19 Within the United States, January-February 2020. MMWR. Available at https://www.who.int/emergencies/diseases/novel-coronavirus-2019/global-research-on-novel-coronavirus-2019-ncov/solidarity-clinical-trial-for-covid-19-treatments . May 29, 2020; Accessed: February 29, 2024.

End of the Federal COVID-19 Public Health Emergency (PHE) Declaration. CDC Centers for Disease Control and Prevention. Available at https://www.cdc.gov/coronavirus/2019-ncov/your-health/end-of-phe.html . 2023 May 05; Accessed: February 29, 2024.

CDC. Coronavirus Disease 2019 (COVID-19): Recommendations for Cloth Face Covers. Centers for Disease Control and Prevention. Available at https://www.cdc.gov/coronavirus/2019-ncov/prevent-getting-sick/cloth-face-cover.html . April 3, 2020; Accessed: February 29, 2024.

Ferguson NM, Laydon D, Nedjati-Gilani G, Imai N, Ainslie K, Baguelin M, et al. Impact of non-pharmaceutical interventions (NPIs) to reduce COVID-19 mortality and healthcare demand. Imperial College COVID-19 Response Team. Available at https://www.imperial.ac.uk/media/imperial-college/medicine/sph/ide/gida-fellowships/Imperial-College-COVID19-NPI-modelling-16-03-2020.pdf . 2020 Mar 16; Accessed: February 29, 2024.

Christie A, Brooks JT, Hicks LA, et al. Guidance for Implementing COVID-19 Prevention Strategies in the Context of Varying Community Transmission Levels and Vaccination Coverage. MMWR Morb Mortal Wkly Rep . 2021. 70:1044–1047. [Full Text] .

Honein MA, Christie A, Rose DA, et al. Summary of guidance for public health strategies to address high levels of community transmission of SARS-CoV-2 and related deaths, December 2020. MMWR Morb Mortal Wkly Rep . 2020 Dec 04. [Full Text] .

Centers for Disease Control and Prevention. How to Protect Yourself & Others. Centers for Disease Control and Prevention. Available at https://www.cdc.gov/coronavirus/2019-ncov/prevent-getting-sick/prevention.html . November 29, 2021; Accessed: February 29, 2024.

CDC. Underlying medical conditions associated with high risk for severe COVID-19: Information for healthcare providers. Centers for Disease Control and Prevention. Available at https://www.cdc.gov/coronavirus/2019-ncov/hcp/clinical-care/underlyingconditions.html . 2021 Mar 29; updated Feb. 9, 2023; Accessed: February 29, 2024.

Tanaka H, Ogata T, Shibata T, Nagai H, Takahashi Y, Kinoshita M, et al. Shorter Incubation Period among COVID-19 Cases with the BA.1 Omicron Variant. Int J Environ Res Public Health . 2022 May 23. 19 (10): [QxMD MEDLINE Link] .

Clinical characteristics of COVID-19. European Centre for Disease Prevention and Control. Available at https://www.ecdc.europa.eu/en/covid-19/latest-evidence/clinical . Updated: 30 May 2023; Accessed: February 20, 2024.

Hentsch L, Cocetta S, Allali G, Santana I, Eason R, Adam E, et al. Breathlessness and COVID-19: A Call for Research. Respiration . 2021. 100 (10):1016-1026. [QxMD MEDLINE Link] .

Zoghi G, Moosavy SH, Yavarian S, HasaniAzad M, Khorrami F, Sharegi Brojeni M, et al. Gastrointestinal implications in COVID-19. BMC Infect Dis . 2021 Nov 4. 21 (1):1135. [QxMD MEDLINE Link] .

Rabin RC. Lost Sense of Smell May Be Peculiar Clue to Coronavirus Infection. The New York Times. Available at https://www.nytimes.com/2020/03/22/health/coronavirus-symptoms-smell-taste.html . March 22, 2020; Accessed: February 29, 2024.

Coelho DH, Reiter ER, French E, Costanzo RM. Decreasing Incidence of Chemosensory Changes by COVID-19 Variant. Otolaryngol Head Neck Surg . 2022 May 3. 1945998221097656. [QxMD MEDLINE Link] .

CDC. 2019 Novel Coronavirus, Wuhan, China: Interim Healthcare Infection Prevention and Control Recommendations for Patients Under Investigation for 2019 Novel Coronavirus. CDC. Available at https://www.cdc.gov/coronavirus/2019-ncov/infection-control.html . January 18, 2020; Accessed: December 1, 2021.

Rizk JG, Forthal DN, Kalantar-Zadeh K, Mehra MR, Lavie CJ, Rizk Y, et al. Expanded Access Programs, compassionate drug use, and Emergency Use Authorizations during the COVID-19 pandemic. Drug Discov Today . 2020 Nov 27. [QxMD MEDLINE Link] . [Full Text] .

Abutaleb Y. How the new coronavirus differs from SARS, measles and Ebola. The Washington Post. Available at https://www.washingtonpost.com/health/how-the-new-coronavirus-differs-from-sars-measles-and-ebola/2020/01/23/aac6bb06-3e1b-11ea-b90d-5652806c3b3a_story.html . January 23, 2020; Accessed: February 20, 2024.

World Health Organization. MERS situation update, February 2022. WHO Regional Office for the Eastern Mediterranean. Available at http://www.emro.who.int/health-topics/mers-cov/mers-outbreaks.html . February 2022; Accessed: May 17, 2022.

WHO. Leading health agencies outline updated terminology for pathogens that transmit through the air. News Release. World Health Organization. Available at https://www.who.int/news/item/18-04-2024-leading-health-agencies-outline-updated-terminology-for-pathogens-that-transmit-through-the-air . April 18, 2024; Accessed: April 25, 2024.

Handiso TB, Jifar MS, Nuriye Hagisso S. Coronavirus's (SARS-CoV-2) airborne transmission. SAGE Open Med . 2022. 10:20503121221094185. [QxMD MEDLINE Link] .

Centers for Disease Control and Prevention. COVID-19 Overview and Infection Prevention and Control Priorities in non-U.S. Healthcare Settings. Centers for Disease Control and Prevention. Available at https://www.cdc.gov/coronavirus/2019-ncov/hcp/non-us-settings/overview/index.html . Updated Oct 27, 2023; Accessed: February 29, 2024.

CDC. Coronavirus Disease 2019: Scientific Brief: SARS-CoV-2 and Potential Airborne Transmission. Centers for Disease Control and Prevention. Centers for Disease Control and Prevention. Available at https://www.cdc.gov/coronavirus/2019-ncov/more/scientific-brief-sars-cov-2.html . 2020 Oct 05; Accessed: December 1, 2021.

Morawska L, Milton DK. It is Time to Address Airborne Transmission of COVID-19. Clin Infect Dis . 2020 Jul 6. [QxMD MEDLINE Link] .

Mask use in the context of COVID-19 (1 December 2020). World Health Organization. Available at https://www.who.int/publications/i/item/advice-on-the-use-of-masks-in-the-community-during-home-care-and-in-healthcare-settings-in-the-context-of-the-novel-coronavirus-(2019-ncov)-outbreak . December 1, 2020; Accessed: February 29, 2024.

van Doremalen N, Bushmaker T, Morris DH, Holbrook MG, Gamble A, Williamson BN, et al. Aerosol and Surface Stability of SARS-CoV-2 as Compared with SARS-CoV-1. N Engl J Med . 2020 Mar 17. [QxMD MEDLINE Link] .

Chin AWH, Chu JTS, Perera MRA, et al. Stability of SARS-CoV-2 in different environmental conditions. The Lancet Microbe . April 2, 2020. [Full Text] .

Rahmani A, Dini G, Leso V, Montecucco A, Kusznir Vitturi B, Iavicoli I, et al. Duration of SARS-CoV-2 shedding and infectivity in the working age population: a systematic review and meta-analysis. Med Lav . 2022 Apr 26. 113 (2):e2022014. [QxMD MEDLINE Link] .

Zhou F, Yu T, Du R, Fan G, Liu Y, Liu Z, et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet . 2020 Mar 11. [QxMD MEDLINE Link] .

Liu Y, Yan LM, Wan L, Xiang TX, Le A, Liu JM, et al. Viral dynamics in mild and severe cases of COVID-19. Lancet Infect Dis . 2020 Mar 19. [QxMD MEDLINE Link] .

Zhou B, She J, Wang Y, Ma X. The duration of viral shedding of discharged patients with severe COVID-19. Clin Infect Dis . 2020 Apr 17. [QxMD MEDLINE Link] .

Mole B. Recovered COVID-19 patients test positive but not infectious, data finds. Ars Technica. Available at https://arstechnica.com/science/2020/05/feared-reactivation-of-covid-19-infections-disputed-by-new-data/ . May 19, 2020; Accessed: February 29, 2024.

Aydillo T, Gonzalez-Reiche AS, Aslam S, van de Guchte A, Khan Z, Obla A, et al. Shedding of Viable SARS-CoV-2 after Immunosuppressive Therapy for Cancer. N Engl J Med . 2020 Dec 24. 383 (26):2586-2588. [QxMD MEDLINE Link] . [Full Text] .

Baang JH, Smith C, Mirabelli C, Valesano AL, Manthei DM, Bachman M, et al. Prolonged SARS-CoV-2 replication in an immunocompromised patient. J Infect Dis . 2020 Oct 22. [QxMD MEDLINE Link] . [Full Text] .

Li D, Jin M, Bao P, Zhao W, Zhang S. Clinical Characteristics and Results of Semen Tests Among Men With Coronavirus Disease 2019. JAMA Netw Open . 2020 May 1. 3 (5):e208292. [QxMD MEDLINE Link] .

Oran DP, Topol EJ. Prevalence of Asymptomatic SARS-CoV-2 Infection : A Narrative Review. Ann Intern Med . 2020 Sep 1. 173 (5):362-367. [QxMD MEDLINE Link] . [Full Text] .

Johansson MA, Quandelacy TM, Kada S, Prasad PV, Steele M, Brooks JT, et al. SARS-CoV-2 Transmission From People Without COVID-19 Symptoms. JAMA Netw Open . 2021 Jan 4. 4 (1):e2035057. [QxMD MEDLINE Link] . [Full Text] .

Zou L, Ruan F, Huang M, Liang L, Huang H, Hong Z, et al. SARS-CoV-2 Viral Load in Upper Respiratory Specimens of Infected Patients. N Engl J Med . 2020 Feb 19. [QxMD MEDLINE Link] .

WHO Coronavirus Disease (COVID-19) Dashboard. World Health Organization. Available at https://covid19.who.int/ . 2023 Apr 05; Accessed: February 29, 2024.

CDC. Coronavirus Disease 2019 (COVID-19) – Cases in the U.S. Centers for Disease Control and Prevention (CDC). Available at https://covid.cdc.gov/covid-data-tracker/#cases_casesper100klast7days . 2023 Mar 29; Accessed: April 5, 2023.

Ahmad FB, Cisewski JA, Miniño A, Anderson RN. Provisional Mortality Data - United States, 2020. MMWR Morb Mortal Wkly Rep . 2021 Apr 9. 70 (14):519-522. [QxMD MEDLINE Link] . [Full Text] .

Ahmad FB, Cisewski JA, Anderson RN. Provisional Mortality Data - United States, 2021. MMWR Morb Mortal Wkly Rep . 2022 Apr 29. 71 (17):597-600. [QxMD MEDLINE Link] . [Full Text] .

Price-Haywood EG, Burton J, Fort D, Seoane L. Hospitalization and Mortality among Black Patients and White Patients with Covid-19. N Engl J Med . 2020 Jun 25. 382 (26):2534-2543. [QxMD MEDLINE Link] . [Full Text] .

Khanijahani A, Iezadi S, Gholipour K, Azami-Aghdash S, Naghibi D. A systematic review of racial/ethnic and socioeconomic disparities in COVID-19. Int J Equity Health . 2021 Nov 24. 20 (1):248. [QxMD MEDLINE Link] .

Zelner J, Trangucci R, Naraharisetti R, Cao A, Malosh R, Broen K, et al. Racial disparities in COVID-19 mortality are driven by unequal infection risks. Clin Infect Dis . 2020 Nov 21. [QxMD MEDLINE Link] . [Full Text] .

Tai DBG, Shah A, Doubeni CA, Sia IG, Wieland ML. The Disproportionate Impact of COVID-19 on Racial and Ethnic Minorities in the United States. Clin Infect Dis . 2020 Jun 20. [QxMD MEDLINE Link] . [Full Text] .

Millet C, Racoosin E, Narvar S, Horani G, et al. The Racial Divide: A Follow Up Study on Racial Disparity Amongst COVID-19 Survivors in an Urban Community. J Community Hosp Intern Med Perspect . 2022 May 2. 12(3):66-70. [QxMD MEDLINE Link] . [Full Text] .

Hobbs CV, Kim SS, Vemula P, Inagaki K, et al. Active Surveillance With Seroprevalence-based Infection Rates Indicates Racial Disparities With Pediatric SARS-CoV-2 Requiring Hospitalization in Mississippi, March 2020-February 2021. Pediatr Infect Dis J . 2022 Jun 7. [QxMD MEDLINE Link] .

Ward LA, Black KP, Britton CL, Tompkins ML, Provost EM. COVID-19 Cases, Hospitalizations, and Deaths Among American Indian or Alaska Native Persons - Alaska, 2020-2021. MMWR Morb Mortal Wkly Rep . 2022 Jun 3. 71 (22):730-733. [QxMD MEDLINE Link] .

Cunningham JW, Vaduganathan M, Claggett BL, Jering KS, Bhatt AS, Rosenthal N, et al. Clinical Outcomes in Young US Adults Hospitalized With COVID-19. JAMA Intern Med . 2020 Sep 9. [QxMD MEDLINE Link] . [Full Text] .

Park YJ, Choe YJ, Park O, and the, COVID-19 National Emergency Response Center, Epidemiology and Case Management Team. Contact Tracing during Coronavirus Disease Outbreak, South Korea, 2020. Emerg Infect Dis . 2020 Oct. 26 (10):2465-2468. [QxMD MEDLINE Link] . [Full Text] .

Schwartz NG, Moorman AC, Makaretz A, Chang KT, Chu VT, Szablewski CM, et al. Adolescent with COVID-19 as the Source of an Outbreak at a 3-Week Family Gathering - Four States, June-July 2020. MMWR Morb Mortal Wkly Rep . 2020 Oct 9. 69 (40):1457-1459. [QxMD MEDLINE Link] . [Full Text] .

Zhu F, Ang JY. COVID-19 Infection in Children: Diagnosis and Management. Curr Infect Dis Rep . 2022 Apr 11. 1-12. [QxMD MEDLINE Link] .

Waghmare A, Hijano DR. SARS-CoV-2 Infection and COVID-19 in Children. Clin Chest Med . 2023 Jun. 44 (2):359-371. [QxMD MEDLINE Link] .

Castagnoli R, Votto M, Licari A, Brambilla I, Bruno R, Perlini S, et al. Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection in Children and Adolescents: A Systematic Review. JAMA Pediatr . 2020 Apr 22. [QxMD MEDLINE Link] .

Aronoff SC, Hall A, Del Vecchio MT. The Natural History of SARS-Cov-2 Related Multisystem Inflammatory Syndrome in Children (MIS-C): A Systematic Review. J Pediatric Infect Dis Soc . 2020 Sep 14. [QxMD MEDLINE Link] . [Full Text] .

Hoang A, Chorath K, Moreira A, Evans M, Burmeister-Morton F, Burmeister F, et al. COVID-19 in 7780 pediatric patients: A systematic review. EClinicalMedicine . 2020 Jul. 24:100433. [QxMD MEDLINE Link] . [Full Text] .

Ahmed M, Advani S, Moreira A, Zoretic S, Martinez J, Chorath K, et al. Multisystem inflammatory syndrome in children: A systematic review. EClinicalMedicine . 2020 Sep 4. 100527. [QxMD MEDLINE Link] . [Full Text] .

Children and COVID-19: State-Level Data Report. American Academy of Pediatrics. Available at https://services.aap.org/en/pages/2019-novel-coronavirus-covid-19-infections/children-and-covid-19-state-level-data-report/ . 2022 Oct 27; Accessed: November 7, 2022.

Hillis SD, Blenkinsop A, Villaveces A, Annor FB, Liburd L, Massetti GM, et al. COVID-19-Associated Orphanhood and Caregiver Death in the United States. Pediatrics . 2021 Oct 7. [QxMD MEDLINE Link] . [Full Text] .

CDC. COVID Data Tracker. Centers for Disease Control and Prevention. Available at https://covid.cdc.gov/covid-data-tracker/#datatracker-home . May 11, 2023; Accessed: March 6, 2024.

Bixler D, Miller AD, Mattison CP, and the, Pediatric Mortality Investigation Team. SARS-CoV-2-Associated Deaths Among Persons Aged MMWR Morb Mortal Wkly Rep</i>. 2020 Sep 18. 69 (37):1324-1329. [QxMD MEDLINE Link] . [Full Text] .

Chao JY, Derespina KR, Herold BC, Goldman DL, Aldrich M, Weingarten J, et al. Clinical Characteristics and Outcomes of Hospitalized and Critically Ill Children and Adolescents with Coronavirus Disease 2019 at a Tertiary Care Medical Center in New York City. J Pediatr . 2020 Aug. 223:14-19.e2. [QxMD MEDLINE Link] . [Full Text] .

Han MS, Choi EH, Chang SH, Jin BL, Lee EJ, Kim BN, et al. Clinical Characteristics and Viral RNA Detection in Children With Coronavirus Disease 2019 in the Republic of Korea. JAMA Pediatr . 2020 Aug 28. [QxMD MEDLINE Link] . [Full Text] .

Jiang L, Tang K, Levin M, Irfan O, Morris SK, Wilson K, et al. COVID-19 and multisystem inflammatory syndrome in children and adolescents. Lancet Infect Dis . 2020 Nov. 20 (11):e276-e288. [QxMD MEDLINE Link] .

Feldstein LR, Tenforde MW, Friedman KG, and the, Overcoming COVID-19 Investigators. Characteristics and Outcomes of US Children and Adolescents With Multisystem Inflammatory Syndrome in Children (MIS-C) Compared With Severe Acute COVID-19. JAMA . 2021 Feb 24. [QxMD MEDLINE Link] . [Full Text] .

Ko JY, DeSisto CL, Simeone RM, Ellington S, Galang RR, Oduyebo T, et al. Adverse Pregnancy Outcomes, Maternal Complications, and Severe Illness Among US Delivery Hospitalizations With and Without a Coronavirus Disease 2019 (COVID-19) Diagnosis. Clin Infect Dis . 2021 Jul 15. 73 (Suppl 1):S24-S31. [QxMD MEDLINE Link] . [Full Text] .

Wang H, Li N, Sun C, Guo X, Su W, Song Q, et al. The association between pregnancy and COVID-19: A systematic review and meta-analysis. Am J Emerg Med . 2022 Apr 6. 56:188-195. [QxMD MEDLINE Link] .

Ayala-Ramírez P, González M, Escudero C, Quintero-Arciniegas L, Giachini FR, Alves de Freitas R, et al. Severe Acute Respiratory Syndrome Coronavirus 2 Infection in Pregnancy. A Non-systematic Review of Clinical Presentation, Potential Effects of Physiological Adaptations in Pregnancy, and Placental Vascular Alterations. Front Physiol . 2022. 13:785274. [QxMD MEDLINE Link] .

DeSisto CL, Wallace B, Simeone RM, Polen K, Ko JY, Meaney-Delman D, et al. Risk for Stillbirth Among Women With and Without COVID-19 at Delivery Hospitalization - United States, March 2020-September 2021. MMWR Morb Mortal Wkly Rep . 2021 Nov 26. 70 (47):1640-1645. [QxMD MEDLINE Link] . [Full Text] .

Marín Gabriel MA, Reyne Vergeli M, Caserío Carbonero S, Sole L, Carrizosa Molina T, Rivero Calle I, et al. Maternal, Perinatal and Neonatal Outcomes With COVID-19: A Multicenter Study of 242 Pregnancies and Their 248 Infant Newborns During Their First Month of Life. Pediatr Infect Dis J . 2020 Sep 11. [QxMD MEDLINE Link] .

Pierce-Williams RAM, Burd J, Felder L, Khoury R, Bernstein PS, Avila K, et al. Clinical course of severe and critical coronavirus disease 2019 in hospitalized pregnancies: a United States cohort study. Am J Obstet Gynecol MFM . 2020 Aug. 2 (3):100134. [QxMD MEDLINE Link] . [Full Text] .

Adhikari EH, Moreno W, Zofkie AC, MacDonald L, McIntire DD, Collins RRJ, et al. Pregnancy Outcomes Among Women With and Without Severe Acute Respiratory Syndrome Coronavirus 2 Infection. JAMA Netw Open . 2020 Nov 2. 3 (11):e2029256. [QxMD MEDLINE Link] .

Chambers C, Krogstad P, Bertrand K, Contreras D, Tobin NH, Bode L, et al. Evaluation for SARS-CoV-2 in Breast Milk From 18 Infected Women. JAMA . 2020 Aug 19. [QxMD MEDLINE Link] . [Full Text] .

Pace RM, Williams JE, Järvinen KM, Meehan CL, Martin MA, Ley SH, et al. Milk From Women Diagnosed With COVID-19 Does Not Contain SARS-CoV-2 RNA but Has Persistent Levels of SARS-CoV-2-Specific IgA Antibodies. Front Immunol . 2021. 12:801797. [QxMD MEDLINE Link] . [Full Text] .

Dandachi D, Geiger G, Montgomery MW, and the, HIV-COVID-19 consortium. Characteristics, Comorbidities, and Outcomes in a Multicenter Registry of Patients with HIV and Coronavirus Disease-19. Clin Infect Dis . 2020 Sep 9. [QxMD MEDLINE Link] . [Full Text] .

Okoh AK, Bishburg E, Grinberg S, Nagarakanti S. COVID-19 Pneumonia in Patients With HIV: A Case Series. J Acquir Immune Defic Syndr . 2020 Sep 1. 85 (1):e4-e5. [QxMD MEDLINE Link] . [Full Text] .

Karmen-Tuohy S, Carlucci PM, Zervou FN, Zacharioudakis IM, Rebick G, Klein E, et al. Outcomes Among HIV-Positive Patients Hospitalized With COVID-19. J Acquir Immune Defic Syndr . 2020 Sep 1. 85 (1):6-10. [QxMD MEDLINE Link] . [Full Text] .

Ho HE, Peluso MJ, Margus C, Matias Lopes JP, He C, Gaisa MM, et al. Clinical outcomes and immunologic characteristics of Covid-19 in people with HIV. J Infect Dis . 2020 Jun 30. [QxMD MEDLINE Link] . [Full Text] .

Oyelade T, Alqahtani JS, Hjazi AM, Li A, Kamila A, Raya RP. Global and Regional Prevalence and Outcomes of COVID-19 in People Living with HIV: A Systematic Review and Meta-Analysis. Trop Med Infect Dis . 2022 Feb 3. 7 (2): [QxMD MEDLINE Link] .

Self WH, Tenforde MW, Stubblefield WB, and the, CDC COVID-19 Response Team IVY Network. Seroprevalence of SARS-CoV-2 among frontline health care personnel in a multistate hospital network – 13 academic medical centers, April-June 2020. MMWR Morb Mortal Wkly Rep . 2020 Aug 31. 69: [Full Text] .

Barron E, Bakhai C, Kar P, Weaver A, Bradley D, Ismail H, et al. Associations of type 1 and type 2 diabetes with COVID-19-related mortality in England: a whole-population study. Lancet Diabetes Endocrinol . 2020 Aug 13. [QxMD MEDLINE Link] . [Full Text] .

O'Hearn M, Liu J, Cudhea F, Micha R, Mozaffarian D. Coronavirus Disease 2019 Hospitalizations Attributable to Cardiometabolic Conditions in the United States: A Comparative Risk Assessment Analysis. J Am Heart Assoc . 2021 Feb. 10 (5):e019259. [QxMD MEDLINE Link] . [Full Text] .

Hui DS, I Azhar E, Madani TA, Ntoumi F, Kock R, Dar O, et al. The continuing 2019-nCoV epidemic threat of novel coronaviruses to global health - The latest 2019 novel coronavirus outbreak in Wuhan, China. Int J Infect Dis . 2020 Jan 14. 91:264-266. [QxMD MEDLINE Link] .

Vangeel L, De Jonghe S, Maes P, Slechten B, Raymenants J, André E, et al. Remdesivir, molnupiravir and nirmatrelvir remain active against SARS-CoV-2 omicron and other variants of concern. bioRxiv . 2021 Dec 28. [Full Text] .

Pulliam JRC, van Schalkwyk C, Govender N, von Gottberg A, Cohen C, Groome MJ, et al. Increased risk of SARS-CoV-2 reinfection associated with emergence of the Omicron variant in South Africa. medRxiv . 2021 Dec 02. [Full Text] .

Wilhelm A, Widera M, Grikscheit K, Toptan T, Schenk B, Pallas C, et al. Reduced neutralization of SARS-CoV-2 omicron variant by vaccine sera and monoclonal antibodies. medRxiv . 2021 Dec 13. [Full Text] .

Cherian S, Potdar V, Jadhav S, Yadav P, Gupta N, Das M, et al. Convergent evolution of SARS-CoV-2 spike mutations, L452R, E484Q and P681R, in the second wave of COVID-19 in Maharashtra, India. bioRxiv . 2021 May 03. [Full Text] .

Edara VV, Lai L, Sahoo MK, Floyd K, Sibai M, Solis D, et al. Infection and vaccine-induced neutralizing antibody responses to the SARS-CoV-2 B.1.617.1 variant. bioRxiv . 2021 May 10. [Full Text] .

Lopez Bernal J, Andrews N, Gower C, Gallagher E, Simmons R, Thelwall S, et al. Effectiveness of Covid-19 Vaccines against the B.1.617.2 (Delta) Variant. N Engl J Med . 2021 Jul 21. [QxMD MEDLINE Link] . [Full Text] .

Volz E, Mishra S, Chand M, Barrett JC, Johnson R, Geidelberg L, et al. Report 42 - Transmission of SARS-CoV-2 Lineage B.1.1.7 in England: Insights from linking epidemiological and genetic data. Imperial College London, MRC Centre for Global Infectious Disease Analysis. Available at https://www.imperial.ac.uk/media/imperial-college/medicine/mrc-gida/2020-12-31-COVID19-Report-42-Preprint-VOC.pdf . 2020 Dec 31; Accessed: December 1, 2021.

Nelson G, Oleksandr B, Spilman P, Niazi K, Rabizadeh S, Soon-Shiong P. Molecular dynamic simulation reveals E484K mutation enhances spike RBD-ACE2 affinity and the combination of E484K, K417N and N401Y mutations (501Y.V2 variant) induces conformational change greater than N401Y mutant alone, potentially resulting in an escape mutant. bioRxiv . 2021 Jan 13. [Full Text] .

Sabino EC, Buss LF, Carvalho MPS, Prete CA, Crispim MAE, Fraiji NA, et al. Resurgence of COVID-19 in Manaus, Brazil, despite high seroprevalence. Lancet . 2021 Jan 27. [Full Text] .

CDC. Symptoms of Coronavirus. CDC. Available at https://www.cdc.gov/coronavirus/2019-ncov/symptoms-testing/symptoms.html . May 13, 2020 (updated March 22, 2022); Accessed: April 29, 2022.

Lauer SA, Grantz KH, Bi Q, Jones FK, Zheng Q, Meredith HR, et al. The Incubation Period of Coronavirus Disease 2019 (COVID-19) From Publicly Reported Confirmed Cases: Estimation and Application. Ann Intern Med . 2020 Mar 10. [QxMD MEDLINE Link] .

Deo R, Choudhary MC, Moser C, and the, ACTIV-2/A5401 Study Team†. Symptom and Viral Rebound in Untreated SARS-CoV-2 Infection. Ann Intern Med . 2023 Feb 21. [QxMD MEDLINE Link] . [Full Text] .

Wu Z, McGoogan JM. Characteristics of and Important Lessons From the Coronavirus Disease 2019 (COVID-19) Outbreak in China: Summary of a Report of 72 314 Cases From the Chinese Center for Disease Control and Prevention. JAMA . 2020 Feb 24. [QxMD MEDLINE Link] .

Wiersinga WJ, Rhodes A, Cheng AC, Peacock SJ, Prescott HC. Pathophysiology, Transmission, Diagnosis, and Treatment of Coronavirus Disease 2019 (COVID-19): A Review. JAMA . 2020 Aug 25. 324 (8):782-793. [QxMD MEDLINE Link] .

Burke RM, Killerby ME, Newton S, Ashworth CE, Berns AL, Brennan S, et al. Symptom Profiles of a Convenience Sample of Patients with COVID-19 - United States, January-April 2020. MMWR Morb Mortal Wkly Rep . 2020 Jul 17. 69 (28):904-908. [QxMD MEDLINE Link] .

CDC. Healthcare Workers: Information on COVID-19. CDC. Available at https://www.cdc.gov/coronavirus/2019-ncov/hcp/index.html . March 31, 2021 (updated); Accessed: December 1, 2021.

Williamson EJ, Walker AJ, Bhaskaran K, et al. OpenSAFELY: factors associated with COVID-19 death in 17 million patients. Nature . 2020 Jul 8. [QxMD MEDLINE Link] .

Hewitt J, Carter B, Vilches-Moraga A, et al. The effect of frailty on survival in patients with COVID-19 (COPE): a multicentre, European, observational cohort study. Lancet Public Health . 2020 Jun 30. [QxMD MEDLINE Link] .

Ellinghaus D, Degenhardt F, Bujanda L, et al. The ABO blood group locus and a chromosome 3 gene cluster associate with SARS-CoV-2 respiratory failure in an Italian-Spanish genome-wide association analysis. medRxiv. Available at https://www.medrxiv.org/content/10.1101/2020.05.31.20114991v1 . June 2, 2020; Accessed: December 1, 2021.

Ellinghaus D, Degenhardt F, Bujanda L, et al. Genomewide Association Study of Severe Covid-19 With Respiratory Failure. NEJM . 2020 Jun 17. [QxMD MEDLINE Link] . [Full Text] .

Spinato G, Fabbris C, Polesel J, Cazzador D, Borsetto D, Hopkins C, et al. Alterations in Smell or Taste in Mildly Symptomatic Outpatients With SARS-CoV-2 Infection. JAMA . 2020 Apr 22. [QxMD MEDLINE Link] .

Luers JC, Rokohl AC, Loreck N, Wawer Matos PA, Augustin M, Dewald F, et al. Olfactory and Gustatory Dysfunction in Coronavirus Disease 19 (COVID-19). Clin Infect Dis . 2020 May 1. [QxMD MEDLINE Link] .

Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet . 2020 Jan 24. [QxMD MEDLINE Link] .

Guan WJ, Ni ZY, Hu Y, et al. Clinical Characteristics of Coronavirus Disease 2019 in China. N Engl J Med . 2020 Feb 28. [QxMD MEDLINE Link] .

Chen N, Zhou M, Dong X, Qu J, Gong F, Han Y, et al. Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study. Lancet . 2020 Feb 15. 395 (10223):507-513. [QxMD MEDLINE Link] .

Wang D, Hu B, Hu C, Zhu F, Liu X, Zhang J, et al. Clinical Characteristics of 138 Hospitalized Patients With 2019 Novel Coronavirus-Infected Pneumonia in Wuhan, China. JAMA . 2020 Feb 7. [QxMD MEDLINE Link] .

CDC. Long-Term Effects of COVID-19. Centers for Disease Control and Prevention. Available at https://www.cdc.gov/coronavirus/2019-ncov/long-term-effects.html . 2020 Nov 13; Accessed: December 1, 2021.

[Guideline] COVID-19 Treatment Guidelines Panel. Clinical Spectrum of SARS-CoV-2 Infection. National Institutes of Health. Available at https://www.covid19treatmentguidelines.nih.gov/overview/clinical-spectrum/ . March 1 2024 (updated); Accessed: February 29, 2024.

[Guideline] COVID-19 rapid guideline: managing the long-term effects of COVID-19. National Institute for Health and Care Excellence (NICE). Available at https://www.nice.org.uk/guidance/NG188 . 2020 Dec 18; Accessed: December 1, 2021.

Datta SD, Talwar A, Lee JT. A Proposed Framework and Timeline of the Spectrum of Disease Due to SARS-CoV-2 Infection: Illness Beyond Acute Infection and Public Health Implications. JAMA . 2020 Dec 8. 324 (22):2251-2252. [QxMD MEDLINE Link] . [Full Text] .

McFadyen JD, Stevens H, Peter K. The Emerging Threat of (Micro)Thrombosis in COVID-19 and Its Therapeutic Implications. Circ Res . 2020 Jul 31. 127 (4):571-587. [QxMD MEDLINE Link] . [Full Text] .

Kotecha T, Knight DS, Razvi Y, Kumar K, Vimalesvaran K, Thornton G, et al. Patterns of myocardial injury in recovered troponin-positive COVID-19 patients assessed by cardiovascular magnetic resonance. Eur Heart J . 2021 Feb 18. [QxMD MEDLINE Link] . [Full Text] .

Sciscent BY, Eisele CD, Ho L, King SD, Jain R, Golamari RR. COVID-19 reinfection: the role of natural immunity, vaccines, and variants. J Community Hosp Intern Med Perspect . 2021. 11 (6):733-739. [QxMD MEDLINE Link] .

Pérez-Lago L, Kestler M, Sola-Campoy PJ, et al. SARS-CoV-2 superinfection and reinfection with three different strains. Transbound Emerg Dis . 2021 Oct 23. [QxMD MEDLINE Link] .

CDC. 2019 Novel Coronavirus, Wuhan, China: Frequently Asked Questions and Answers. CDC. Available at https://www.cdc.gov/coronavirus/2019-ncov/faq.html . October 19, 2021; Accessed: December 1, 2021.

FDA. Coronavirus (COVID-19) Update: Daily Roundup. fda.gov. Available at https://www.fda.gov/news-events/press-announcements/coronavirus-covid-19-update-daily-roundup . March 23, 2020; Accessed: December 1, 2021.

Wu C, Chen X, Cai Y, Xia J, Zhou X, Xu S, et al. Risk Factors Associated With Acute Respiratory Distress Syndrome and Death in Patients With Coronavirus Disease 2019 Pneumonia in Wuhan, China. JAMA Intern Med . 2020 Mar 13. [QxMD MEDLINE Link] .

Shi H, Han X, Jiang N, Cao Y, Alwalid O, Gu J, et al. Radiological findings from 81 patients with COVID-19 pneumonia in Wuhan, China: a descriptive study. Lancet Infect Dis . 2020 Feb 24. [QxMD MEDLINE Link] .

Zhao W, Zhong Z, Xie X, Yu Q, Liu J. Relation Between Chest CT Findings and Clinical Conditions of Coronavirus Disease (COVID-19) Pneumonia: A Multicenter Study. AJR Am J Roentgenol . 2020 Mar 3. 1-6. [QxMD MEDLINE Link] .

Bai HX, Hsieh B, Xiong Z, Halsey K, Choi JW, Tran TML, et al. Performance of radiologists in differentiating COVID-19 from viral pneumonia on chest CT. Radiology . 2020 Mar 10. 200823. [QxMD MEDLINE Link] .

ACR. ACR Recommendations for the use of Chest Radiography and Computed Tomography (CT) for Suspected COVID-19 Infection. American College of Radiology. Available at https://www.acr.org/Advocacy-and-Economics/ACR-Position-Statements/Recommendations-for-Chest-Radiography-and-CT-for-Suspected-COVID19-Infection . March 22, 2020; Accessed: December 1, 2021.

Hu Z, Song C, Xu C, Jin G, Chen Y, Xu X, et al. Clinical characteristics of 24 asymptomatic infections with COVID-19 screened among close contacts in Nanjing, China. Sci China Life Sci . 2020 Mar 4. [QxMD MEDLINE Link] .

Wang Y, Liu Y, Liu L, Wang X, Luo N, Ling L. Clinical outcome of 55 asymptomatic cases at the time of hospital admission infected with SARS-Coronavirus-2 in Shenzhen, China. J Infect Dis . 2020 Mar 17. [QxMD MEDLINE Link] .

Li M, Lei P, Zeng B, Li Z, Yu P, Fan B, et al. Coronavirus Disease (COVID-19): Spectrum of CT Findings and Temporal Progression of the Disease. Acad Radiol . 2020 Mar 20. [QxMD MEDLINE Link] .

Wong HYF, Lam HYS, Fong AH, Leung ST, Chin TW, Lo CSY, et al. Frequency and Distribution of Chest Radiographic Findings in COVID-19 Positive Patients. Radiology . 2019 Mar 27. 201160. [QxMD MEDLINE Link] .

Bogoch II, Watts A, Thomas-Bachli A, Huber C, Kraemer MUG, Khan K. Pneumonia of Unknown Etiology in Wuhan, China: Potential for International Spread Via Commercial Air Travel. J Travel Med . 2020 Jan 14. [QxMD MEDLINE Link] .

Veklury (remdesivir) [package insert]. Foster City, CA: Gilead Sciences, Inc. February 2024. Available at [Full Text] .

RECOVERY Collaborative Group., Horby P, Lim WS, Emberson JR, et al. Dexamethasone in Hospitalized Patients with Covid-19. N Engl J Med . 2021 Feb 25. 384 (8):693-704. [QxMD MEDLINE Link] . [Full Text] .

WHO. The use of non-steroidal anti-inflammatory drugs (NSAIDs) in patients with COVID-19. WHO. Available at https://www.who.int/news-room/commentaries/detail/the-use-of-non-steroidal-anti-inflammatory-drugs-(nsaids)-in-patients-with-covid-19 . April 19, 2020; Accessed: December 1, 2021.

[Guideline] Bhimraj A, Morgan RL, Shumaker AH, et al. Infectious Diseases Society of America Guidelines on the Treatment and Management of Patients with COVID-19. IDSA. Available at https://www.idsociety.org/practice-guideline/covid-19-guideline-treatment-and-management/ . 2021 Oct 01; updated 6/26/2023; Accessed: February 29, 2024.

Gordon DE, Jang GM, Bouhaddou M, Xu J, Obernier K, O’Mera MJ, et al. A SARS-CoV-2-Human Protein-Protein Interaction Map Reveals Drug Targets and Potential Drug-Repurposing. bioRxiv. Available at https://www.biorxiv.org/content/10.1101/2020.03.22.002386v1 . 2020 Mar 22; Accessed: December 1, 2021.

Arshad U, Pertinez H, Box H, Tatham L, Rajoki RKR, Curley P, et al. Prioritisation of potential anti-SARS-CoV-2 drug repurposing opportunities based on ability to achieve adequate target site concentrations derived from their established human pharmacokinetics. medRxiv . 2020 Apr 22. [Full Text] .

World Health Organization. “Solidarity” clinical trial for COVID-19 treatments. WHO. Available at https://www.who.int/emergencies/diseases/novel-coronavirus-2019/global-research-on-novel-coronavirus-2019-ncov/solidarity-clinical-trial-for-covid-19-treatments . 2020 Oct 16; Accessed: December 1, 2021.

WHO Solidarity Trial Consortium. Repurposed Antiviral Drugs for Covid-19 - Interim WHO Solidarity Trial Results. N Engl J Med . 2020 Dec 2. [QxMD MEDLINE Link] . [Full Text] .

Kalil AC. Treating COVID-19-Off-Label Drug Use, Compassionate Use, and Randomized Clinical Trials During Pandemics. JAMA . 2020 Mar 24. [QxMD MEDLINE Link] . [Full Text] .

Rome BN, Avorn J. Drug Evaluation during the Covid-19 Pandemic. N Engl J Med . 2020 Apr 14. [QxMD MEDLINE Link] . [Full Text] .

Frellick M. Key Drugs Join PPEs on List of Front-Line Shortages. Medscape Medical News . 2020 Apr 02. Available at https://www.medscape.com/viewarticle/928039 .

Live Updates: Which Drugs Are In Shortage Because of COVID-19?. GoodRx. Available at https://www.goodrx.com/blog/covid-19-drug-shortages-updates/ . July 13, 2020; Accessed: December 1, 2021.

Wilson FP. Hydroxychloroquine for COVID-19: What’s the Evidence? (Commentary). Medscape Medical News and Perspectives . 2020 Mar 25. Available at https://www.medscape.com/viewarticle/927342 .

CDC. Coronavirus Disease 2019 (COVID-19): Community-Related Exposures. Centers for Disease Control and Prevention. Available at https://www.cdc.gov/coronavirus/2019-ncov/php/public-health-recommendations.html . March 1, 2021 (updated); Accessed: December 1, 2021.

CDC. Coronavirus Disease 2019 (COVID-19): Travel-Associated Exposures. Centers for Disease Control and Prevention. Available at https://www.cdc.gov/coronavirus/2019-ncov/php/risk-assessment.html . November 5, 2021 (updated); Accessed: December 1, 2021.

Leung NHL, Chu DKW, Shiu EYC, et al. Respiratory virus shedding in exhaled breath and efficacy of face masks. Nat Med . 2020. [Full Text] .

Smith JD, MacDougall CC, Johnstone J, Copes RA, Schwartz B, Garber GE. Effectiveness of N95 respirators versus surgical masks in protecting health care workers from acute respiratory infection: a systematic review and meta-analysis. CMAJ . 2016 May 17. 188 (8):567-574. [QxMD MEDLINE Link] .

TLR 2/6/9 agonist PUL-042. NCI Drug Dictionary. Available at https://www.cancer.gov/publications/dictionaries/cancer-drug/def/tlr-2-6-9-agonist-pul-042 . Accessed: December 1, 2021.

The Use PUL-042 Inhalation Solution to Prevent COVID-19 in Adults Exposed to SARS-CoV-2. ClinicalTrials.gov. Available at https://clinicaltrials.gov/ct2/show/NCT04313023 . 2020 Mar 24; Accessed: December 1, 2021.

The Use of PUL-042 Inhalation Solution to Reduce the Severity of COVID-19 in Adults Positive for SARS-CoV-2 Infection. ClinicalTrials.gov. Available at https://clinicaltrials.gov/ct2/show/NCT04312997?term=PUL-042&cond=COVID&cntry=US&draw=2&rank=2 . 2020 May 07; Accessed: December 1, 2021.

Holshue ML, DeBolt C, Lindquist S, and, the Washington State 2019-nCoV Case Investigation Team. First Case of 2019 Novel Coronavirus in the United States. N Engl J Med . 2020 Mar 5. 382 (10):929-936. [QxMD MEDLINE Link] .

National Institutes of Health. NIH clinical trial of remdesivir to treat COVID-19 begins. U.S. Department of Health and Human Services. Available at https://www.nih.gov/news-events/news-releases/nih-clinical-trial-remdesivir-treat-covid-19-begins . 2020 Feb 25; Accessed: March 24, 2020.

Beigel JH, Tomashek KM, Dodd LE, Mehta AK, Zingman BS, Kalil AC, et al. Remdesivir for the Treatment of Covid-19 - Final Report. N Engl J Med . 2020 Oct 8. [QxMD MEDLINE Link] . [Full Text] .

Harrington DP, Baden LR, Hogan JW. A Large, Simple Trial Leading to Complex Questions. N Engl J Med . 2020 Dec 2. [QxMD MEDLINE Link] . [Full Text] .

Ader F, Bouscambert-Duchamp M, Hites M, and the, DisCoVeRy Study Group. Remdesivir plus standard of care versus standard of care alone for the treatment of patients admitted to hospital with COVID-19 (DisCoVeRy): a phase 3, randomised, controlled, open-label trial. Lancet Infect Dis . 2021 Sep 14. [QxMD MEDLINE Link] . [Full Text] .

Goldman JD, Lye DCB, Hui DS, Marks KM, Bruno R, Montejano R, et al. Remdesivir for 5 or 10 Days in Patients with Severe Covid-19. N Engl J Med . November 5, 2020. 383:1827-1837. [QxMD MEDLINE Link] . [Full Text] .

Spinner CD, Gottlieb RL, Criner GJ, and the, GS-US-540-5774 Investigators. Effect of Remdesivir vs Standard Care on Clinical Status at 11 Days in Patients With Moderate COVID-19: A Randomized Clinical Trial. JAMA . 2020 Aug 21. [QxMD MEDLINE Link] . [Full Text] .

Gottlieb RL, Vaca CE, Paredes R, and the, GS-US-540-9012 (PINETREE) Investigators. Early Remdesivir to Prevent Progression to Severe Covid-19 in Outpatients. N Engl J Med . 2021 Dec 22. [QxMD MEDLINE Link] . [Full Text] .

Veklury (remdesivir) reduced risk of mortality in hospitalized COVID-19 patients across all variant time periods in a real world study of more than 500,000 patients. Gilead . 2023 Jan 21. Available at https://www.gilead.com/news-and-press/press-room/press-releases/2023/2/veklury-remdesivir-reduced-risk-of-mortality-in-hospitalized-covid19-patients-across-all-variant-time-periods-in-a-real-world-study-of-more-than-5 .

Amstutz A, et al. Effects of remdesivir in patients hospitalised with COVID-19: a systematic review and individual patient data meta-analysis of randomized controlled trials. Lancet Respir Med . 2023 Feb 21. [Full Text] .

Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of Remdesivir (GS-5734) in Participants From Birth to < 18 Years of Age With Coronavirus Disease 2019 (COVID-19) (CARAVAN). ClinicalTrials.gov. Available at https://www.clinicaltrials.gov/ct2/show/NCT04431453 . 2020 Jun 01; Accessed: December 1, 2021.

Chiotos K, Hayes M, Kimberlin DW, Jones SB, James SH, Pinninti SG, et al. Multicenter interim guidance on use of antivirals for children with COVID-19/SARS-CoV-2. J Pediatric Infect Dis Soc . 2020 Sep 12. [QxMD MEDLINE Link] . [Full Text] .

Burwick RM, Yawetz S, Stephenson KE, Collier AY, Sen P, Blackburn BG, et al. Compassionate Use of Remdesivir in Pregnant Women with Severe Covid-19. Clin Infect Dis . 2020 Oct 8. [QxMD MEDLINE Link] . [Full Text] .

McCoy JA, Short WR, Srinivas SK, Levine LD, Hirshberg A. Compassionate use of remdesivir for treatment of severe coronavirus disease 2019 in pregnant women at a United States academic center. Am J Obstet Gynecol MFM . 2020 Aug. 2 (3):100164. [QxMD MEDLINE Link] . [Full Text] .

Hammond J, Leister-Tebbe H, Gardner A, and the, EPIC-HR Investigators. Oral Nirmatrelvir for High-Risk, Nonhospitalized Adults with Covid-19. N Engl J Med . 2022 Feb 16. [QxMD MEDLINE Link] . [Full Text] .

Pfizer announces additional phase 2/3 study results confirming robust efficacy of novel COVID-19 oral antiviral treatment candidate in reducing risk of hospitalization or death. Pfizer, Inc . 2021 Dec 14. Available at https://www.pfizer.com/news/press-release/press-release-detail/pfizer-announces-additional-phase-23-study-results .

A post-exposure prophylaxis study of PF-07321332/ritonavir in adult household contacts of an individual with symptomatic COVID-19. ClinicalTrials.gov. Available at https://www.clinicaltrials.gov/ct2/show/NCT05047601 . 2021 Dec 01; Accessed: December 14, 2021.

Xie Y, Choi T, Al-Aly Z. Nirmatrelvir and the risk of post-acute sequelae of COVID-19. medRxiv . November 5, 2022. [Full Text] .

Liu J, Pan X, Zhang S, Li M, Ma K, Fan C, et al. Efficacy and safety of Paxlovid in severe adult patients with SARS-Cov-2 infection: a multicenter randomized controlled study. Lancet Reg Health West Pac . 2023 Feb 6. 100694. [QxMD MEDLINE Link] . [Full Text] .

Wong CKH, Lau KTK, Au ICH, Lau EHY, Poon LLM, Hung IFN, et al. Viral burden rebound in hospitalised patients with COVID-19 receiving oral antivirals in Hong Kong: a population-wide retrospective cohort study. Lancet Infect Dis . 2023 Feb 13. [QxMD MEDLINE Link] . [Full Text] .

Zheng Q, Ma P, Wang M, Cheng Y, Zhou M, Ye L, et al. Efficacy and safety of Paxlovid for COVID-19:a meta-analysis. J Infect . 2023 Jan. 86 (1):66-117. [QxMD MEDLINE Link] . [Full Text] .

Jayk Bernal A, Gomes da Silva MM, Musungaie DB, and the, MOVe-OUT Study Group. Molnupiravir for Oral Treatment of Covid-19 in Nonhospitalized Patients. N Engl J Med . 2022 Feb 10. 386:509-520. [QxMD MEDLINE Link] . [Full Text] .

Xie Y, Bowe B, Al-Aly Z. Molnupiravir and risk of hospital admission or death in adults with covid-19: emulation of a randomized target trial using electronic health records. BMJ . 2023 Mar 7. 380:e072705. [QxMD MEDLINE Link] . [Full Text] .

Najjar-Debbiny R, Gronich N, Weber G, Khoury J, Amar M, Stein N, et al. Effectiveness of Molnupiravir in High-Risk Patients: A Propensity Score Matched Analysis. Clin Infect Dis . 2023 Feb 8. 76 (3):453-460. [QxMD MEDLINE Link] . [Full Text] .

Merck provides update on phase 3 MOVe-AHEAD trial evaluating Lagevrio (molnupiravir) for post-exposure prophylaxis for prevention of COVID-19. Merck . 2023 Feb 21. Available at https://www.merck.com/news/merck-provides-update-on-phase-3-move-ahead-trial-evaluating-lagevrio-molnupiravir-for-post-exposure-prophylaxis-for-prevention-of-covid-19/ .

Ingraham NE, Lotfi-Emran S, Thielen BK, Techar K, Morris RS, Holtan SG, et al. Immunomodulation in COVID-19. Lancet Respir Med . 2020 May 4. [QxMD MEDLINE Link] . [Full Text] .

Rizk JG, Kalantar-Zadeh K, Mehra MR, Lavie CJ, Rizk Y, Forthal DN. Pharmaco-Immunomodulatory Therapy in COVID-19. Drugs . 2020 Sep. 80 (13):1267-1292. [QxMD MEDLINE Link] . [Full Text] .

Peterson JH, Paranjape NS, Grundlingh N, Priestley JL. Outcomes and Adverse Effects of Baricitinib Versus Tocilizumab in the Management of Severe COVID-19. Crit Care Med . 2023 Mar 1. 51 (3):337-346. [QxMD MEDLINE Link] . [Full Text] .

Cawcutt KA, Kalil AC. Baricitinib or Tocilizumab? Treatment of Patients Hospitalized With Severe COVID-19. Crit Care Med . 2023 Mar 1. 51 (3):413-415. [QxMD MEDLINE Link] .

Stebbing J, Phelan A, Griffin I, Tucker C, Oechsle O, Smith D, et al. COVID-19: combining antiviral and anti-inflammatory treatments. Lancet Infect Dis . 2020 Apr. 20 (4):400-402. [QxMD MEDLINE Link] . [Full Text] .

Richardson P, Griffin I, Tucker C, Smith D, Oechsle O, Phelan A, et al. Baricitinib as potential treatment for 2019-nCoV acute respiratory disease. Lancet . 2020 Feb 15. 395 (10223):e30-e31. [QxMD MEDLINE Link] . [Full Text] .

Stebbing J, Krishnan V, de Bono S, Ottaviani S, Casalini G, Richarson PJ, et al. Mechanism of baricitinib supports artificial intelligence-predicted testing in COVID-19 patients. 2020 Apr 15. [Full Text] .

Kalil AC, Patterson TF, Mehta AK, Tomashek KM, Wolfe CR, Ghazaryan V, et al. Baricitinib plus Remdesivir for Hospitalized Adults with Covid-19. N Engl J Med . 2020 Dec 11. [QxMD MEDLINE Link] . [Full Text] .

Kalil AC, Stebbing J. Baricitinib: the first immunomodulatory treatment to reduce COVID-19 mortality in a placebo-controlled trial. Lancet Respir Med . 2021 Aug 31. [QxMD MEDLINE Link] . [Full Text] .

Marconi VC, Ramanan AV, de Bono S, Kartman CE, Krishnan V, Liao R, et al. Efficacy and safety of baricitinib for the treatment of hospitalised adults with COVID-19 (COV-BARRIER): a randomised, double-blind, parallel-group, placebo-controlled phase 3 trial. Lancet Respir Med . 2021 Aug 31. [QxMD MEDLINE Link] . [Full Text] .

Lilly and Incyte’s baricitinib reduced deaths among patients with COVID-19 receiving invasive mechanical ventilation. Lilly. Available at https://investor.lilly.com/news-releases/news-release-details/lilly-and-incytes-baricitinib-reduced-deaths-among-patients . 2021 Aug 03; Accessed: December 1, 2021.

Guimarães PO, Quirk D, Furtado RH, and the STOP-COVID Trial Investigators. Tofacitinib in patients hospitalized with COVID-19 pneumonia. N Engl J Med . 2021 Jun 16. [QxMD MEDLINE Link] . [Full Text] .

Wagner JL, Veve MP, Barber KE. Using IL-6 inhibitors to treat COVID-19. ContagionLive. Available at https://www.contagionlive.com/publications/contagion/2020/august/using-il6-inhibitors-to-treat-covid19?ekey=c2NiZXJnbWFuQG5lYnJhc2thbWVkLmNvbQ . 2020 Aug 17; Accessed: December 1, 2021.

[Guideline] NIH. The COVID-19 Treatment Guidelines Panel’s Statement on the Use of Tocilizumab (and Other Interleukin-6 Inhibitors) for the Treatment of COVID-19. COVID-19 Treatment Guidelines. Available at https://www.covid19treatmentguidelines.nih.gov/immune-based-therapy/interleukin-6-inhibitors/ . 2021 Mar 05; Accessed: December 1, 2021.

Salama C, Han J, Yau L, Reiss WG, Kramer B, Neidhart JD, et al. Tocilizumab in Patients Hospitalized with Covid-19 Pneumonia. N Engl J Med . 2021 Jan 7. 384 (1):20-30. [QxMD MEDLINE Link] . [Full Text] .

Rosas IO, Diaz G, Gottlieb RL, Lobo SM, Robinson P, Hunter BD, et al. Tocilizumab and remdesivir in hospitalized patients with severe COVID-19 pneumonia: a randomized clinical trial. Intensive Care Med . 2021 Nov. 47 (11):1258-1270. [QxMD MEDLINE Link] . [Full Text] .

REMAP-CAP Investigators., Gordon AC, Mouncey PR, Al-Beidh F, et al. Interleukin-6 Receptor Antagonists in Critically Ill Patients with Covid-19. N Engl J Med . 2021 Apr 22. 384 (16):1491-1502. [QxMD MEDLINE Link] . [Full Text] .

RECOVERY Collaborative Group. Tocilizumab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial. Lancet . 2021 May 1. 397 (10285):1637-1645. [QxMD MEDLINE Link] . [Full Text] .

Rosas IO, Bräu N, Waters M, Go RC, Hunter BD, Bhagani S, et al. Tocilizumab in Hospitalized Patients with Severe Covid-19 Pneumonia. N Engl J Med . 2021 Apr 22. 384 (16):1503-1516. [QxMD MEDLINE Link] . [Full Text] .

Rubin EJ, Longo DL, Baden LR. Interleukin-6 Receptor Inhibition in Covid-19 - Cooling the Inflammatory Soup. N Engl J Med . 2021 Apr 22. 384 (16):1564-1565. [QxMD MEDLINE Link] . [Full Text] .

[Guideline] NIH. Interleukin-1 Inhibitors. COVID-19 Treatment Guidelines. Available at https://www.covid19treatmentguidelines.nih.gov/immune-based-therapy/interleukin-1-inhibitors/ . 2020 Jul 17; Accessed: September 8, 2021.

[Guideline] Clinical management of severe acute respiratory infection when novel coronavirus (nCoV) infection is suspected. World Health Organization. Available at https://www.who.int/publications-detail/clinical-management-of-severe-acute-respiratory-infection-when-novel-coronavirus-(ncov)-infection-is-suspected . 2020 Mar 13; Accessed: March 24, 2020.

Russell CD, Millar JE, Baillie JK. Clinical evidence does not support corticosteroid treatment for 2019-nCoV lung injury. Lancet . 2020 Feb 15. 395 (10223):473-475. [QxMD MEDLINE Link] .

[Guideline] Alhazzani W, Evans L, Alshamsi F, Møller MH, Ostermann M, Prescott HC, et al. Surviving Sepsis Campaign Guidelines on the Management of Adults With Coronavirus Disease 2019 (COVID-19) in the ICU: First Update. Crit Care Med . 2021 Mar 1. 49 (3):e219-e234. [QxMD MEDLINE Link] . [Full Text] .

WHO Rapid Evidence Appraisal for COVID-19 Therapies (REACT) Working Group. Association Between Administration of Systemic Corticosteroids and Mortality Among Critically Ill Patients With COVID-19: A Meta-analysis. JAMA . 2020 Sep 2. [QxMD MEDLINE Link] . [Full Text] .

Prescott HC, Rice TW. Corticosteroids in COVID-19 ARDS: Evidence and Hope During the Pandemic. JAMA . 2020 Sep 2. [QxMD MEDLINE Link] . [Full Text] .

[Guideline] WHO. Corticosteroids for COVID-19 – Living Guidance. World Health Organization. Available at https://www.who.int/publications/i/item/WHO-2019-nCoV-Corticosteroids-2020.1 . 2020 Sep 02; Accessed: December 1, 2021.

Afzali B, Noris M, Lambrecht BN, Kemper C. The state of complement in COVID-19. Nat Rev Immunol . 2022 Feb. 22 (2):77-84. [QxMD MEDLINE Link] . [Full Text] .

Carvelli J, Demaria O, Vély F, Batista L, Chouaki Benmansour N, Fares J, et al. Association of COVID-19 inflammation with activation of the C5a-C5aR1 axis. Nature . 2020 Dec. 588 (7836):146-150. [QxMD MEDLINE Link] . [Full Text] .

Aiello S, Gastoldi S, Galbusera M, Ruggenenti P, Portalupi V, Rota S, et al. C5a and C5aR1 are key drivers of microvascular platelet aggregation in clinical entities spanning from aHUS to COVID-19. Blood Adv . 2022 Jan 8. 6 (3):866-881. [QxMD MEDLINE Link] . [Full Text] .

Vlaar APJ, Witzenrath M, van Paassen P, and the, PANAMO study group. Anti-C5a antibody (vilobelimab) therapy for critically ill, invasively mechanically ventilated patients with COVID-19 (PANAMO): a multicentre, double-blind, randomised, placebo-controlled, phase 3 trial. Lancet Respir Med . 2022 Dec. 10 (12):1137-1146. [QxMD MEDLINE Link] . [Full Text] .

Strich JR, Tian X, Samour M, King CS, Shlobin O, Reger R, et al. Fostamatinib for the treatment of hospitalized adults with COVD-19 A randomized trial. Clin Infect Dis . 2021 Sep 1. [QxMD MEDLINE Link] . [Full Text] .

Reis G, Moreira Silva EAS, Medeiros Silva DC, and the, TOGETHER Investigators. Early Treatment with Pegylated Interferon Lambda for Covid-19. N Engl J Med . 2023 Feb 9. 388 (6):518-528. [QxMD MEDLINE Link] . [Full Text] .

Kalil AC, Mehta AK, Patterson TF, and the, ACTT-3 study group members. Efficacy of interferon beta-1a plus remdesivir compared with remdesivir alone in hospitalised adults with COVID-19: a double-bind, randomised, placebo-controlled, phase 3 trial. Lancet Respir Med . 2021 Oct 18. [QxMD MEDLINE Link] . [Full Text] .

Schönbeck U, Libby P. Inflammation, immunity, and HMG-CoA reductase inhibitors: statins as antiinflammatory agents?. Circulation . 2004 Jun 1. 109 (21 Suppl 1):II18-26. [QxMD MEDLINE Link] . [Full Text] .

Hariyanto TI, Kurniawan A. Statin therapy did not improved the in-hospital outcome of coronavirus disease 2019 (COVID-19) infection. Diabetes Metab Syndr . 2020 Aug 26. 14(6):1613-1615. [QxMD MEDLINE Link] . [Full Text] .

Kow CS, Hasan SS. Meta-analysis of Effect of Statins in Patients with COVID-19. Am J Cardiol . 2020 Aug 12. [QxMD MEDLINE Link] . [Full Text] .

Castiglione V, Chiriacò M, Emdin M, Taddei S, Vergaro G. Statin therapy in COVID-19 infection. Eur Heart J Cardiovasc Pharmacother . 2020 Jul 1. 6 (4):258-259. [QxMD MEDLINE Link] . [Full Text] .

[Guideline] NIH. Covid-19 Treatment Guidelines - Adjunctive Therapy. National Institutes of Health. Available at https://www.covid19treatmentguidelines.nih.gov/adjunctive-therapy/ . 2020 Jul 17; Accessed: December 1, 2021.

Yao JS, Paguio JA, Dee EC, Tan HC, Moulick A, Milazzo C, et al. The minimal effect of zinc on the survival of hospitalized patients with Covid-19: an observational study. Chest . 2020 Jul 22. [QxMD MEDLINE Link] . [Full Text] .

Meltzer DO, Best TJ, Zhang H, Vokes T, Arora V, Solway J. Association of Vitamin D Status and Other Clinical Characteristics With COVID-19 Test Results. JAMA Netw Open . 2020 Sep 1. 3 (9):e2019722. [QxMD MEDLINE Link] . [Full Text] .

Sahota O. Understanding vitamin D deficiency. Age Ageing . 2014 Sep. 43 (5):589-91. [QxMD MEDLINE Link] . [Full Text] .

Bishop CW, Ashfaq A, Melnick JZ, Vazquez-Escarpanter E, Fialkow JA, Strugnell SA, et al. Results from the REsCUe trial: a randomized controlled trial with extended-release calcifediol in symptomatic outpatients with COVID-19. medRXiv . 2022 Feb 05. [Full Text] .

NIH COVID-19 Treatment Guidelines Panel. Statement on the emergency use authorization of convalescent plasma for the treatment of COVID-19. National Institutes of Health. Available at https://www.covid19treatmentguidelines.nih.gov/statement-on-convalescent-plasma-eua/ . 2022 Dec 01; Accessed: February 1, 2023.

Senefeld JW, Franchini M, Mengoli C, Cruciani M, Zani M, Gorman EK, et al. COVID-19 Convalescent Plasma for the Treatment of Immunocompromised Patients: A Systematic Review and Meta-analysis. JAMA Netw Open . 2023 Jan 3. 6 (1):e2250647. [QxMD MEDLINE Link] . [Full Text] .

Writing Committee for the REMAP-CAP Investigators, Estcourt LJ, Turgeon AF, McQuilten ZK, et al. Effect of Convalescent Plasma on Organ Support-Free Days in Critically Ill Patients With COVID-19: A Randomized Clinical Trial. JAMA . 2021 Oct 4. [QxMD MEDLINE Link] .

A Study to Investigate the Prevention of COVID-19 with VYD222 in Adults With Immune Compromise and in Participants Aged 12 Years or Older Who Are at Risk of Exposure to SARS-CoV-2. ClinicalTrials.gov. Available at https://classic.clinicaltrials.gov/ct2/show/NCT06039449 . 2024 January 18; Accessed: April 1, 2024.

Levin MJ, Ustianowski A, De Wit S, and the, PROVENT Study Group. Intramuscular AZD7442 (Tixagevimab-Cilgavimab) for Prevention of Covid-19. N Engl J Med . 2022 Jun 9. 386 (23):2188-2200. [QxMD MEDLINE Link] . [Full Text] .

Young-Xu Y, Epstein L, Marconi VC, Davey V, Zwain G, Smith J, et al. Tixagevimab/cilagavimab for prevention of COVID-19 during the omicron surge: Retrospective analysis of national VA electronic data. medRxiv . 2022 May 29. [Full Text] .

Westendorf K, Žentelis S, Wang L, Foster D, Vaillancourt P, Wiggin M, et al. LY-CoV1404 (bebtelovimab) potently neutralizes SARS-CoV-2 variants. Cell Rep . 2022 May 17. 39 (7):110812. [QxMD MEDLINE Link] . [Full Text] .

Gupta A, Gonzalez-Rojas Y, Juarez E, and the, COMET-ICE Investigators. Early Treatment for Covid-19 with SARS-CoV-2 Neutralizing Antibody Sotrovimab. N Engl J Med . 2021 Nov 18. 385 (21):1941-1950. [QxMD MEDLINE Link] . [Full Text] .

GSK and Vir submit emergency use authorization application to FDA for intramuscular administration of sotrovimab for the early treatment of COVID-19. GlaxoSmithKline . 2022 Jan 13. Available at https://us.gsk.com/en-us/media/press-releases/gsk-and-vir-submit-emergency-use-authorization-application-to-fda-for-intramuscular-administration-of-sotrovimab-for-the-early-treatment-of-covid-19/ .

O'Brien MP, Forleo-Neto E, Musser BJ, and the, Covid-19 Phase 3 Prevention Trial Team. Subcutaneous REGEN-COV Antibody Combination to Prevent Covid-19. N Engl J Med . 2021 Aug 4. [QxMD MEDLINE Link] . [Full Text] .

Weinreich DM, Sivapalasingam S, Norton T, Ali S, Gao H, Bhore R, et al. REGN-COV2, a Neutralizing Antibody Cocktail, in Outpatients with Covid-19. N Engl J Med . 2020 Dec 17. [QxMD MEDLINE Link] . [Full Text] .

RECOVERY Collaborative Group, Horby PW, Mafham M, Peto L, et al. Casirivimab and imdevimab in patients admitted to hospital with COVID-19 (RECOVERY): a randomized, controlled, open-label, platform trial. medRxiv . 2021 Jun 16. [Full Text] .

Dougan M, Nirula A, Azizad M, and the, BLAZE-1 Investigators. Bamlanivimab plus Etesevimab in Mild or Moderate Covid-19. N Engl J Med . 2021 Oct 7. 385 (15):1382-1392. [QxMD MEDLINE Link] . [Full Text] .

Cohen MS, Nirula A, Mulligan MJ, and the, BLAZE-2 Investigators. Effect of Bamlanivimab vs Placebo on Incidence of COVID-19 Among Residents and Staff of Skilled Nursing and Assisted Living Facilities: A Randomized Clinical Trial. JAMA . 2021 Jul 6. 326 (1):46-55. [QxMD MEDLINE Link] . [Full Text] .

Lurie N, Saville M, Hatchett R, Halton J. Developing Covid-19 Vaccines at Pandemic Speed. N Engl J Med . 2020 May 21. 382 (21):1969-1973. [QxMD MEDLINE Link] . [Full Text] .

Koirala A, Joo YJ, Khatami A, Chiu C, Britton PN. Vaccines for COVID-19: The current state of play. Paediatr Respir Rev . 2020 Sep. 35:43-49. [QxMD MEDLINE Link] . [Full Text] .

Iba T, Levy JH, Levi M, Connors JM, Thachil J. Coagulopathy of Coronavirus Disease 2019. Crit Care Med . 2020 Sep. 48 (9):1358-1364. [QxMD MEDLINE Link] . [Full Text] .

Katneni UK, Alexaki A, Hunt RC, Schiller T, DiCuccio M, Buehler PW, et al. Coagulopathy and Thrombosis as a Result of Severe COVID-19 Infection: A Microvascular Focus. Thromb Haemost . 2020 Aug 24. [QxMD MEDLINE Link] . [Full Text] .

Ferguson J, Volk S, Vondracek T, Flanigan J, Chernaik A. Empiric therapeutic anticoagulation and mortality in critically ill patients with respiratory failure from SARS-CoV-2: A retrospective cohort study. J Clin Pharmacol . 2020 Sep 3. [QxMD MEDLINE Link] . [Full Text] .

Paranjpe I, Fuster V, Lala A, Russak AJ, Glicksberg BS, Levin MA, et al. Association of Treatment Dose Anticoagulation With In-Hospital Survival Among Hospitalized Patients With COVID-19. J Am Coll Cardiol . 2020 Jul 7. 76 (1):122-124. [QxMD MEDLINE Link] . [Full Text] .

NIH ACTIV-4B COVID-19 outpatient thrombosis prevention trial ends early. Brigham Health . 2021 Jun 22. Available at https://www.brighamandwomens.org/about-bwh/newsroom/press-releases-detail?id=3925 .

REMAP-CAP Investigators, ACTIV-4a Investigators, ATTACC Investigators, Goligher EC, Bradbury CA, McVerry BJ, et al. Therapeutic Anticoagulation with Heparin in Critically Ill Patients with Covid-19. N Engl J Med . 2021 Aug 4. [QxMD MEDLINE Link] . [Full Text] .

ATTACC Investigators, ACTIV-4a Investigators, REMAP-CAP Investigators, Lawler PR, Goligher EC, Berger JS, et al. Therapeutic Anticoagulation with Heparin in Noncritically Ill Patients with Covid-19. N Engl J Med . 2021 Aug 4. [QxMD MEDLINE Link] . [Full Text] .

Assessing Safety, Hospitalization and Efficacy of rNAPc2 in COVID-19 (ASPEN). ClinicalTrials.gov. Available at https://www.clinicaltrials.gov/ct2/show/NCT04655586 . 2021 Nov 03; Accessed: December 6, 2021.

Zhou P, Yang XL, Wang XG, Hu B, Zhang L, Zhang W, et al. A pneumonia outbreak associated with a new coronavirus of probable bat origin. Nature . 2020 Mar. 579 (7798):270-273. [QxMD MEDLINE Link] . [Full Text] .

Lopes RD, Macedo AVS, de Barros E Silva PGM, Moll-Bernardes RJ, Feldman A, D'Andréa Saba Arruda G, et al. Continuing versus suspending angiotensin-converting enzyme inhibitors and angiotensin receptor blockers: Impact on adverse outcomes in hospitalized patients with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)--The BRACE CORONA Trial. Am Heart J . 2020 Aug. 226:49-59. [QxMD MEDLINE Link] . [Full Text] .

Clerkin KJ, Fried JA, Raikhelkar J, Sayer G, Griffin JM, Masoumi A, et al. Coronavirus Disease 2019 (COVID-19) and Cardiovascular Disease. Circulation . 2020 Mar 21. [QxMD MEDLINE Link] . [Full Text] .

Fang L, Karakiulakis G, Roth M. Correction to Lancet Respir Med 2020; 8: e21. Lancet Respir Med . 2020 Jun. 8 (6):e54. [QxMD MEDLINE Link] . [Full Text] .

Kuba K, Imai Y, Rao S, Gao H, Guo F, Guan B, et al. A crucial role of angiotensin converting enzyme 2 (ACE2) in SARS coronavirus-induced lung injury. Nat Med . 2005 Aug. 11 (8):875-9. [QxMD MEDLINE Link] . [Full Text] .

Vaduganathan M, Vardeny O, Michel T, McMurray JJV, Pfeffer MA, Solomon S. Renin–Angiotensin–Aldosterone System Inhibitors in Patients with Covid-19. N Engl J Med . 2020 March 30. [QxMD MEDLINE Link] . [Full Text] .

Ishiyama Y, Gallagher PE, Averill DB, Tallant EA, Brosnihan KB, Ferrario CM. Upregulation of angiotensin-converting enzyme 2 after myocardial infarction by blockade of angiotensin II receptors. Hypertension . 2004 May. 43 (5):970-6. [QxMD MEDLINE Link] . [Full Text] .

Ferrario CM, Jessup J, Chappell MC, Averill DB, Brosnihan KB, Tallant EA, et al. Effect of angiotensin-converting enzyme inhibition and angiotensin II receptor blockers on cardiac angiotensin-converting enzyme 2. Circulation . 2005 May 24. 111 (20):2605-10. [QxMD MEDLINE Link] . [Full Text] .

Klimas J, Olvedy M, Ochodnicka-Mackovicova K, Kruzliak P, Cacanyiova S, Kristek F, et al. Perinatally administered losartan augments renal ACE2 expression but not cardiac or renal Mas receptor in spontaneously hypertensive rats. J Cell Mol Med . 2015 Aug. 19 (8):1965-74. [QxMD MEDLINE Link] . [Full Text] .

Walters TE, Kalman JM, Patel SK, Mearns M, Velkoska E, Burrell LM. Angiotensin converting enzyme 2 activity and human atrial fibrillation: increased plasma angiotensin converting enzyme 2 activity is associated with atrial fibrillation and more advanced left atrial structural remodelling. Europace . 2017 Aug 1. 19 (8):1280-1287. [QxMD MEDLINE Link] . [Full Text] .

Burchill LJ, Velkoska E, Dean RG, Griggs K, Patel SK, Burrell LM. Combination renin-angiotensin system blockade and angiotensin-converting enzyme 2 in experimental myocardial infarction: implications for future therapeutic directions. Clin Sci (Lond) . 2012 Dec. 123 (11):649-58. [QxMD MEDLINE Link] .

Bozkurt B, Kovacs R, Harrington B. Joint HFSA/ACC/AHA Statement Addresses Concerns Re: Using RAAS Antagonists in COVID-19. J Card Fail . 2020 May. 26 (5):370. [QxMD MEDLINE Link] . [Full Text] .

Sama IE, Ravera A, Santema BT, van Goor H, Ter Maaten JM, Cleland JGF, et al. Circulating plasma concentrations of angiotensin-converting enzyme 2 in men and women with heart failure and effects of renin-angiotensin-aldosterone inhibitors. Eur Heart J . 2020 May 14. 41 (19):1810-1817. [QxMD MEDLINE Link] . [Full Text] .

Baral R, Tsampasian V, Debski M, Moran B, Garg P, Clark A, et al. Association Between Renin-Angiotensin-Aldosterone System Inhibitors and Clinical Outcomes in Patients With COVID-19: A Systematic Review and Meta-analysis. JAMA Netw Open . 2021 Mar 1. 4 (3):e213594. [QxMD MEDLINE Link] . [Full Text] .

Torres A, Blasi F, Dartois N, Akova M. Which individuals are at increased risk of pneumococcal disease and why? Impact of COPD, asthma, smoking, diabetes, and/or chronic heart disease on community-acquired pneumonia and invasive pneumococcal disease. Thorax . 2015 Oct. 70 (10):984-9. [QxMD MEDLINE Link] . [Full Text] .

Drucker DJ. Coronavirus infections and type 2 diabetes-shared pathways with therapeutic implications. Endocr Rev . 2020 Apr 15. [QxMD MEDLINE Link] . [Full Text] .

Muniyappa R, Gubbi S. COVID-19 Pandemic, Corona Viruses, and Diabetes Mellitus. Am J Physiol Endocrinol Metab . 2020 Mar 31. [QxMD MEDLINE Link] . [Full Text] .

DPP4 dipeptidyl peptidase 4. National Center for Biotechnology Information (NCBI). Available at https://www.ncbi.nlm.nih.gov/gene/1803 . 2020 Apr 20; Accessed: 2020 Apr 21.

RECOVERY Collaborative Group. Lopinavir-ritonavir in patients admitted to hospital with COVID-19 (RECOVERY): a randomized, controlled, open-label, platform trial. The Lancet . 2020 Oct 05. [Full Text] .

Momekov G, Momekova D. Ivermectin as a potential COVID-19 treatment from the pharmacokinetic point of view: antiviral levels are not likely attainable with known dosing regimens. Biotechnology & Biotechnological Equipment. 2020 . 2020. 34(1):469-74. [Full Text] .

Chaccour C, Hammann F, Ramón-García S, Rabinovich NR. Ivermectin and Novel Coronavirus Disease (COVID-19): Keeping Rigor in Times of Urgency. Am J Trop Med Hyg . 2020 Apr 16. [QxMD MEDLINE Link] . [Full Text] .

López-Medina E, López P, Hurtado IC, Dávalos DM, Ramirez O, Martínez E, et al. Effect of Ivermectin on Time to Resolution of Symptoms Among Adults With Mild COVID-19: A Randomized Clinical Trial. JAMA . 2021 Apr 13. 325 (14):1426-1435. [QxMD MEDLINE Link] . [Full Text] .

Lim SCL, Hor CP, Tay KH, and the, I-TECH Study Group. Efficacy of Ivermectin Treatment on Disease Progression Among Adults With Mild to Moderate COVID-19 and Comorbidities: The I-TECH Randomized Clinical Trial. JAMA Intern Med . 2022 Feb 18. [QxMD MEDLINE Link] . [Full Text] .

Reis G, Silva EASM, Silva DCM, and the, TOGETHER Investigators. Effect of Early Treatment with Ivermectin among Patients with Covid-19. N Engl J Med . 2022 May 5. 386 (18):1721-1731. [QxMD MEDLINE Link] . [Full Text] .

Naggie S, Boulware DR, Lindsell CJ, for the, Accelerating COVID-19 Therapeutic Interventions and Vaccines (ACTIV-6) Study Group and Investigators. Effect of Ivermectin vs Placebo on Time to Sustained Recovery in Outpatients With Mild to Moderate COVID-19: A Randomized Clinical Trial. JAMA . 2022 Oct 25. 328 (16):1595-1603. [QxMD MEDLINE Link] . [Full Text] .

Naggie S, Boulware DR, Lindsell CJ, for the, Accelerating Covid-19 Therapeutic Interventions and Vaccines (ACTIV)-6 Study Group and Investigators. Effect of Higher-Dose Ivermectin for 6 Days vs Placebo on Time to Sustained Recovery in Outpatients With COVID-19: A Randomized Clinical Trial. JAMA . 2023 Feb 20. [QxMD MEDLINE Link] . [Full Text] .

Bramante CT, Huling JD, Tignanelli CJ, for the COVID-OUT Trial Team. Randomized Trial of Metformin, Ivermectin, and Fluvoxamine for Covid-19. N Eng J Med . 2022. 387:599-610. [Full Text] .

Reis G, Dos Santos Moreira-Silva EA, Silva DCM, and the, TOGETHER investigators. Effect of early treatment with fluvoxamine on risk of emergency care and hospitalisation among patients with COVID-19: the TOGETHER randomised, platform clinical trial. Lancet Glob Health . 2022 Jan. 10 (1):e42-e51. [QxMD MEDLINE Link] . [Full Text] .

McCarthy MW, Naggie S, Boulware DR, and the, Accelerating COVID-19 Therapeutic Interventions and Vaccines (ACTIV)-6 Study Group and Investigators. Effect of Fluvoxamine vs Placebo on Time to Sustained Recovery in Outpatients With Mild to Moderate COVID-19: A Randomized Clinical Trial. JAMA . 2023 Jan 24. 329 (4):296-305. [QxMD MEDLINE Link] .

Golan Y, Campos JAS, Woolson R, Cilla D, Hanabergh R, Gonzales-Rojas Y, et al. Favipiravir in Patients With Early Mild-to-moderate Coronavirus Disease 2019 (COVID-19): A Randomized Controlled Trial. Clin Infect Dis . 2023 Feb 8. 76 (3):e10-e17. [QxMD MEDLINE Link] . [Full Text] .

Ray WA, Murray KT, Hall K, Arbogast PG, Stein CM. Azithromycin and the risk of cardiovascular death. N Engl J Med . 2012 May 17. 366 (20):1881-90. [QxMD MEDLINE Link] . [Full Text] .

Simpson TF, Kovacs RJ, Stecker EC. Ventricular Arrhythmia Risk Due to Hydroxychloroquine-Azithromycin Treatment For COVID-19. American College of Cardiology; Cardiology Magazine. Available at https://www.acc.org/latest-in-cardiology/articles/2020/03/27/14/00/ventricular-arrhythmia-risk-due-to-hydroxychloroquine-azithromycin-treatment-for-covid-19 . 2020 Mar 29; Accessed: April 1, 2020.

[Guideline] Roden DM, Harrington RA, Poppas A, Russo AM. Considerations for Drug Interactions on QTc in Exploratory COVID-19 (Coronavirus Disease 2019) Treatment. Circulation . 2020 Apr 8. [QxMD MEDLINE Link] . [Full Text] .

[Guideline] Giudicessi JR, Noseworthy PA, Friedman PA, Ackerman MJ. Urgent guidance for navigating and circumventing the QTc prolonging and torsadogenic potential of possible pharmacotherapies for COVID-19. Mayo Clin Proc . 2020 Apr 07. [Full Text] .

Mercuro NJ, Yen CF, Shim DJ, Maher TR, McCoy CM, Zimetbaum PJ, et al. Risk of QT Interval Prolongation Associated With Use of Hydroxychloroquine With or Without Concomitant Azithromycin Among Hospitalized Patients Testing Positive for Coronavirus Disease 2019 (COVID-19). JAMA Cardiol . 2020 May 1. [QxMD MEDLINE Link] . [Full Text] .

Chorin E, Dai M, Shulman E, Wadhwani L, et al. The QT Interval in Patients with SARS-CoV-2 Infection Treated with Hydroxychloroquine/Azithromycin. medRxiv . 2020 Apr 03. [Full Text] .

Borba M, de Almeida Val F, Sampaio VS, Alexandre MA, Melo GC, Brito M, et al. Chloroquine diphosphate in two different dosages as adjunctive therapy of hospitalized patients with severe respiratory syndrome in the context of coronavirus (SARS-CoV-2) infection: Preliminary safety results of a randomized, double-blinded, phase IIb clinical trial (CloroCovid-19 Study). MedRxiv . 2020 Apr 11. [Full Text] .

Lane JCE, Weaver J, Kostka K, Duarte-Salles T, Abrahao MTF, Alghoul H, et al. Safety of hydroxychloroquine, alone and in combination with azithromycin, in light of rapid wide-spread use for COVID-19: a multinational, network cohort and self-controlled case series study. medRxiv . 2020 Apr 10. [Full Text] .

Supady A, Weber E, Rieder M, Lother A, Niklaus T, Zahn T, et al. Cytokine adsorption in patients with severe COVID-19 pneumonia requiring extracorporeal membrane oxygenation (CYCOV): a single centre, open-label, randomised, controlled trial. Lancet Respir Med . 2021 Jul. 9 (7):755-762. [QxMD MEDLINE Link] . [Full Text] .

Matson J, Lange P, Honore PM, Chung KK. Adverse outcomes with extracorporeal adsorbent blood treatments in toxic systemic inflammation: a perspective on possible mechanisms. Ann Intensive Care . 2022 Nov 12. 12 (1):105. [QxMD MEDLINE Link] . [Full Text] .

Zhang Q, et al. Cellular nanosponges inhibit SARS-CoV-2 infectivity. Nano Lett . 2020 Jun 17. [QxMD MEDLINE Link] . [Full Text] .

[Guideline] Centers for Disease Control and Prevention. Interim guidelines for collecting, handling, and testing clinical specimens from persons for coronavirus disease 2019 (COVID-19). CDC. Available at https://www.cdc.gov/coronavirus/2019-nCoV/lab/guidelines-clinical-specimens.html . 2020 Nov 05; Accessed: November 16, 2020.

[Guideline] Center for Clinical Standards and Quality/Quality, Safety & Oversight Group. Guidance for Infection Control and Prevention Concerning Coronavirus Disease (COVID-19): FAQs and Considerations for Patient Triage, Placement and Hospital Discharge. Available at https://www.cms.gov/files/document/qso-20-13-hospitalspdf.pdf-2 . March 4, 2020; Accessed: March 4, 2020.

Puopolo KM, Hudak ML, Kimberlin DW, Cummings J. Management of Infants Born to Mothers with COVID-19. American Academy of Pediatrics. Available at https://downloads.aap.org/AAP/PDF/COVID%2019%20Initial%20Newborn%20Guidance.pdf . April 2, 2020; Accessed: April 3, 2020.

[Guideline] AAP. FAQs: Management of Infants Born to Mothers with Suspected or Confirmed COVID-19. American Academy of Pediatrics. Available at https://services.aap.org/en/pages/2019-novel-coronavirus-covid-19-infections/faqs-management-of-infants-born-to-covid-19-mothers/ . May 21, 2020; Accessed: May 27, 2020.

[Guideline] COVID-19 Treatment Guidelines Panel. Coronavirus Disease 2019 (COVID-19) Treatment Guidelines. National Institutes of Health. Available at https://www.covid19treatmentguidelines.nih.gov/ . 2021 Mar 05; Accessed: March 12, 2021.

[Guideline] Moores LK, Tritschler T, Brosnahan S, Carrier M, Collen JF, Doerschug K, et al. Prevention, diagnosis and treatment of venous thromboembolism in patients with COVID-19: CHEST Guideline and Expert Panel Report. Chest . 2020 Jun 2. [QxMD MEDLINE Link] . [Full Text] .

[Guideline] Thachil J, Tang N, Gando S, Falanga A, Cattaneo M, Levi M, et al. ISTH interim guidance on recognition and management of coagulopathy in COVID-19. J Thromb Haemost . 2020 May. 18 (5):1023-1026. [QxMD MEDLINE Link] . [Full Text] .

[Guideline] COVID-19 Treatment Guidelines Panel. Antithrombotic Therapy in Patients with COVID-19. National Institutes of Health. Available at https://www.covid19treatmentguidelines.nih.gov/antithrombotic-therapy/ . 2021 Feb 11; Accessed: June 28, 2021.

World Health Organization. Roadmap to improve and ensure good indoor ventilation in COVID-19 context (1 March 2021). World Health Organization. Available at https://www.who.int/publications/i/item/9789240021280 . March 1, 2021; Accessed: February 20, 2024.

Lim EHT, Vlaar APJ, Bos LDJ, and the, Amsterdam UMC COVID-19 Biobank Investigators. Anti-C5a antibody vilobelimab treatment and the effect on biomarkers of inflammation and coagulation in patients with severe COVID-19: a substudy of the  phase 2 PANAMO trial. Respir Res . 2022 Dec 24. 23 (1):375. [QxMD MEDLINE Link] . [Full Text] .

Management Strategies in Children and Adolescents with Mild to Moderate COVID-19. American Academy of Pediatri cs. Available at https://www.aap.org/en/pages/2019-novel-coronavirus-covid-19-infections/clinical-guidance/outpatient-covid-19-management-strategies-in-children-and-adolescents/ . Updated February 8, 2023; Accessed: March 6, 2024.

Huang YH, Kuo HC. Kawasaki Disease, MIS-C and COVID-19. Children (Basel) . 2023 Sep 22. 10 (10): [QxMD MEDLINE Link] . [Full Text] .

Simbar M, Nazarpour S, Sheidaei A. Evaluation of pregnancy outcomes in mothers with COVID-19 infection: a systematic review and meta-analysis. J Obstet Gynaecol . 2023 Dec. 43 (1):2162867. [QxMD MEDLINE Link] .

Rojas-Suarez J, Miranda J. Coronavirus Disease-2019 in Pregnancy. Clin Chest Med . 2023 Jun. 44 (2):373-384. [QxMD MEDLINE Link] .

He YF, Liu JQ, Hu XD, Li HM, Wu N, Wang J, et al. Breastfeeding vs. breast milk transmission during COVID-19 pandemic, which is more important?. Front Pediatr . 2023. 11:1253333. [QxMD MEDLINE Link] . [Full Text] .

Weiss A, Donnachie E, Beyerlein A, Ziegler AG, Bonifacio E. Type 1 Diabetes Incidence and Risk in Children With a Diagnosis of COVID-19. JAMA . 2023 Jun 20. 329 (23):2089-2091. [QxMD MEDLINE Link] .

Lippi G, Sanchis-Gomar F, Henry BM. COVID-19 and its long-term sequelae: what do we know in 2023?. Pol Arch Intern Med . 2023. 133: [Full Text] .

Brolly J, Chadwick DR. COVID-19 infection in people living with HIV. Br Med Bull . 2023 Sep 12. 147 (1):20-30. [QxMD MEDLINE Link] . [Full Text] .

• The heart is normal in size. There are diffuse, patchy opacities throughout both lungs, which may represent multifocal viral/bacterial pneumonia versus pulmonary edema. These opacities are particularly confluent along the periphery of the right lung. There is left midlung platelike atelectasis. Obscuration of the left costophrenic angle may represent consolidation versus a pleural effusion with atelectasis. There is no pneumothorax.
• The heart is normal in size. There are bilateral hazy opacities, with lower lobe predominance. These findings are consistent with multifocal/viral pneumonia. No pleural effusion or pneumothorax are seen.
• The heart is normal in size. Patchy opacities are seen throughout the lung fields. Patchy areas of consolidation at the right lung base partially silhouettes the right diaphragm. There is no effusion or pneumothorax. Degenerative changes of the thoracic spine are noted.
• The same patient as above 10 days later.
• The trachea is in midline. The cardiomediastinal silhouette is normal in size. There are diffuse hazy reticulonodular opacities in both lungs. Differential diagnoses include viral pneumonia, multifocal bacterial pneumonia or ARDS. There is no pleural effusion or pneumothorax.
• Axial chest CT demonstrates patchy ground-glass opacities with peripheral distribution.
• Coronal reconstruction chest CT of the same patient above, showing patchy ground-glass opacities.
• Axial chest CT shows bilateral patchy consolidations (arrows), some with peripheral ground-glass opacity. Findings are in peripheral and subpleural distribution.
• Table 1. SARS-CoV-2 Monoclonal Antibodies – inactive EUAs

Contributor Information and Disclosures

David J Cennimo, MD, FAAP, FACP, FIDSA, AAHIVS Associate Professor of Medicine and Pediatrics, Adult and Pediatric Infectious Diseases, Rutgers New Jersey Medical School David J Cennimo, MD, FAAP, FACP, FIDSA, AAHIVS is a member of the following medical societies: American Academy of HIV Medicine , American Academy of Pediatrics , American College of Physicians , American Medical Association , HIV Medicine Association , Infectious Diseases Society of America , Medical Society of New Jersey , Pediatric Infectious Diseases Society Disclosure: Nothing to disclose.

Scott J Bergman, PharmD, FCCP, FIDSA, BCPS, BCIDP Antimicrobial Stewardship Program Coordinator, Infectious Diseases Pharmacy Residency Program Director, Department of Pharmaceutical and Nutrition Care, Division of Infectious Diseases, Nebraska Medicine; Clinical Associate Professor, Department of Pharmacy Practice, College of Pharmacy, University of Nebraska Medical Center Scott J Bergman, PharmD, FCCP, FIDSA, BCPS, BCIDP is a member of the following medical societies: American Association of Colleges of Pharmacy , American College of Clinical Pharmacy , American Pharmacists Association , American Society for Microbiology , American Society of Health-System Pharmacists , Infectious Diseases Society of America , Society of Infectious Diseases Pharmacists Disclosure: Received research grant from: Merck & Co., Inc.

Keith M Olsen, PharmD, FCCP, FCCM Dean and Professor, College of Pharmacy, University of Nebraska Medical Center Disclosure: Nothing to disclose.

Mary L Windle, PharmD Adjunct Associate Professor, University of Nebraska Medical Center College of Pharmacy; Editor-in-Chief, Medscape Drug Reference Disclosure: Nothing to disclose.

Michael Stuart Bronze, MD David Ross Boyd Professor and Chairman, Department of Medicine, Stewart G Wolf Endowed Chair in Internal Medicine, Department of Medicine, University of Oklahoma Health Science Center; Master of the American College of Physicians; Fellow, Infectious Diseases Society of America; Fellow of the Royal College of Physicians, London Michael Stuart Bronze, MD is a member of the following medical societies: Alpha Omega Alpha , American College of Physicians , American Medical Association , Association of Professors of Medicine , Infectious Diseases Society of America , Oklahoma State Medical Association , Southern Society for Clinical Investigation Disclosure: Nothing to disclose.

Molly Marie Miller, PharmD Clinical Infectious Diseases Pharmacist Practitioner, Nebraska Medicine Molly Marie Miller, PharmD is a member of the following medical societies: Society of Infectious Diseases Pharmacists Disclosure: Nothing to disclose.

What would you like to print?

• Print this section
• Print the entire contents of
• Print the entire contents of article

• COVID-19 Variants
• COVID-19 Pulmonary Management
• COVID-19 Reinfections
• Coronavirus Disease 2019 (COVID-19)
• Long Coronavirus 2019 (COVID-19)
• Symptoms and Management of Coronavirus Disease 2019 (COVID-19) FAQ
• Coronavirus Disease 2019 (COVID-19) Radiologic Images
• Picture of COVID-19 in Europe Is Complex
• Global Consensus Reached on COVID-19 Vaccine Updates
• The ED Sailed Smoothly in the Early COVID-19 Days

• Drug Interaction Checker
• Pill Identifier
• Calculators

• 2010comirnaty-covid-19-vaccine-mRNA-pfizer-4000140Drugs Drugs COVID-19 vaccine, mRNA-Pfizer

• 2010covid-19-vaccine-xvv-1-5-mrna-pfizer-4000394Drugs Drugs COVID-19 vaccine XBB.1.5, mRNA-Pfizer
• 2010covid-19-vaccine-xvv-1-5-mrna-moderna-4000395Drugs Drugs COVID-19 vaccine XBB.1.5, mRNA-Moderna

We use cookies on this website to enhance your experience. You can find out more about how we use cookies here

Preventing COVID-19: Refresher Presentations for Schools and Childcare Settings

Understanding how COVID-19 is transmitted and ensuring that proper public health measures are in place is important for preventing the spread of COVID-19 in schools and childcare settings. This presentation series provides those working in school and childcare settings a refresher about the public health practices that help prevent and control the spread of COVID-19. Implementing all recommended public health measures is important to help prevent the spread of COVID-19 in your facilities (i.e., no single measure should be relied on by itself).  Below you will find links to the recorded presentations as well as a downloadable copy of the presentation slides.

COVID-19 Transmission

An overview of how COVID-19 is spread, measures to reduce the risk of spread and implications for infection prevention and control (IPAC) in schools and child care settings.

• Duration: 9 min
• Updated 3 Sep 2021
• View the full transcript

Presentation

Hand Hygiene

Hand Hygiene: The Importance of Cleaning Hands

• Duration: 8 min

The role of cleaning your hands in preventing the spread of COVID-19 as well as review of the proper technique for cleaning your hands and hand care.

Physical Distancing

Environmental Cleaning

• Duration: 7 min

Considerations for cleaning and disinfecting surfaces in school and child care settings.

Communications

[email protected]

• Media Centre

Don’t have a MyPHO account? Register Now

You must be logged in and have the correct access level to access this product.

Login or Register

• Weill Cornell Medicine

Medicine Grand Rounds: COVID-19 presentations

A video of this lecture is available online to members of the Weill Cornell community. You will need to provide your CWID and password. Below are the PowerPoints that were included in the presentation.

• SUGGESTED TOPICS
• The Magazine
• Newsletters
• Managing Yourself
• Managing Teams
• Work-life Balance
• The Big Idea
• Data & Visuals
• Reading Lists
• Case Selections
• HBR Learning
• Topic Feeds
• Account Settings
• Email Preferences

How to Make a “Good” Presentation “Great”

• Guy Kawasaki

Remember: Less is more.

A strong presentation is so much more than information pasted onto a series of slides with fancy backgrounds. Whether you’re pitching an idea, reporting market research, or sharing something else, a great presentation can give you a competitive advantage, and be a powerful tool when aiming to persuade, educate, or inspire others. Here are some unique elements that make a presentation stand out.

• Fonts: Sans Serif fonts such as Helvetica or Arial are preferred for their clean lines, which make them easy to digest at various sizes and distances. Limit the number of font styles to two: one for headings and another for body text, to avoid visual confusion or distractions.
• Colors: Colors can evoke emotions and highlight critical points, but their overuse can lead to a cluttered and confusing presentation. A limited palette of two to three main colors, complemented by a simple background, can help you draw attention to key elements without overwhelming the audience.
• Pictures: Pictures can communicate complex ideas quickly and memorably but choosing the right images is key. Images or pictures should be big (perhaps 20-25% of the page), bold, and have a clear purpose that complements the slide’s text.
• Layout: Don’t overcrowd your slides with too much information. When in doubt, adhere to the principle of simplicity, and aim for a clean and uncluttered layout with plenty of white space around text and images. Think phrases and bullets, not sentences.

As an intern or early career professional, chances are that you’ll be tasked with making or giving a presentation in the near future. Whether you’re pitching an idea, reporting market research, or sharing something else, a great presentation can give you a competitive advantage, and be a powerful tool when aiming to persuade, educate, or inspire others.

• Guy Kawasaki is the chief evangelist at Canva and was the former chief evangelist at Apple. Guy is the author of 16 books including Think Remarkable : 9 Paths to Transform Your Life and Make a Difference.

Partner Center

60 Effective PowerPoint Presentation Tips & Tricks (Giant List)

Here's a PowerPoint presentation tips and tricks guide that takes you through how to make a good PowerPoint presentation.

The best PowerPoint presentations shouldn’t be remembered. Instead, they should fall into the background to support you and the message you’re trying to get across.

Unlike good PowerPoint presentations , bad PowerPoint presentations are a distraction. You may remember them, but not in a good way.

You’ve seen them before. They might have millions of lines of text. Or a disjointed flow to the slides. Even worse, some slides feature ugly photos and poor design that detract from the message you’re trying to get across. That can even hurt your credibility as a professional or speaker.

This article will take you from finding your initial topic to learning how to make a great PowerPoint presentation. Our guide covers everything in between so that you learn how to present a PowerPoint like a pro.

These Microsoft PowerPoint presentation tips and guidelines are organized into sections. So cut straight to the advice you need and come back when you’re ready for the next steps.

Guide to Making Great Presentations (Free eBook Download)

Also, download our Free eBook: The Complete Guide to Making Great Presentations . It’s the deepest resource for learning effective presentation skills for a PPT.

This eBook covers the complete presentation process. It takes the PowerPoint tips and tricks you learn in this article further. Learn how to write your presentation, design it like a pro, and prepare it to present powerfully. It’s another great source for presentation design tips.

Master PowerPoint (Free Course): 15 Essential Tips

This article is full of helpful tips so you can build a powerful presentation. You can also find more PowerPoint tips in this video lesson:

To learn even more about how to make a PowerPoint look good, review the huge list of tips below.

What Makes a PowerPoint Presentation Effective?

Knowing how to use PowerPoint and work within it quickly is helpful. But more important is making a good presentation that hits all your goals. A great PowerPoint presentation is:

• Prepared to Win . Research, plan, and prepare your presentation professionally. It helps you deliver an effective message to your target audience.
• Designed Correctly . Your visual points should stand out without overwhelming your audience. A good PowerPoint visual shouldn’t complicate your message.
• Practiced to Perfection . Rehearse your timing and delivery so that your points land as practiced with a live audience.
• Delivered With Poise . Present with a relaxed inner calm and confident outward projection. Give your audience warmth, excitement, and energy.
• Free From Mistakes . Avoid typos, cheesy clip art, and mistakes like reading directly from your slides.

Consider this your all-inclusive guide to how to make a good presentation. We’ll look at preparing your presentation and explore how to design it in PowerPoint. Plus, we’ll cover how to practice and nail your delivery successfully come presentation time.

We’ll also address what not to do in these tips for PowerPoint presentations—so you can sidestep any big mistakes. Now let’s dig into these tips for effective PowerPoint presentations.

Killer Presentation Preparation Tips to Get Started Right

Before even opening PowerPoint, start by addressing these things. These Microsoft PowerPoint tips and tricks will ensure that you’re prepared for your presentation:

1. Know Your Stuff

Your presentation isn’t about your slides alone. It’s about the message you want to get across. Before filling in stats, facts and figures, think about the narrative that’ll be discussed, why, and in what order.

2. Write It Out

Start in a Word or Google doc, and storyboard or script the entire presentation. This will give you an idea of how the information presented will flow and how viewers will see it in sequence. Learn the complete writing process .

3. Highlight What’s Most Important

A presentation covers the most crucial pieces only. Whatever you’ve been working on that led to this—a paper, a work project, a new product design—doesn’t need to be shared in its entirety. Pick key points and put the rest in an “Appendix” to refer to during the Q&A session at the end.

4. Know Your Audience

How you talk to a room full of medical professionals should be different from the way you address a room full of young entrepreneurs. Everything, in fact, is different: your topic selection, the language you use, the examples you give to illustrate points. The little bits of humor you include should be tailored specifically with your target audience in mind.

Understand your audience’s needs to create a successful PowerPoint presentation. Customize your content to meet their specific requirements.

5. Rehearse! (Yes, Already)

It’s never too early to get used to the rhythm of your presentation and take note of points you want to emphasize. While saying it out loud, you’ll start to develop a “feel” for the material. You’ll notice that some things work well, while others don’t and might need to be worked around.

6. Rewrite After You Rehearse

As you’re rehearsing your presentation, you’re bound to stumble over sections that don’t quite flow naturally. Instead of reworking your delivery, it might be time to consider the content and rewrite the areas that served as stumbling blocks.

“Editing is hard. ‘It’s good enough,’ is a phrase wannabes use. Leaders take editing seriously.” – Anthony Trendl

The most important part of creating a great presentation is the writing stage. The second most important stage is rewriting.

7. Share With a Friend

If the stakes are high for your presentation, it’s never too early to get feedback from those that you trust. Here’s an article that helps you collaborate as a team on a PowerPoint presentation. Get PowerPoint design tips from those that you trust when you collaborate.

Simple Tips to Design Your PowerPoint Presentation Better

Second only to you (the information you bring and how you present it) is your PowerPoint slides. If not designed well, a PowerPoint can be disengaging or distracting (regardless of the content quality). Here are some presentation design tips to make sure this doesn’t happen to you:

8. Keep Your Slides Simple

This is one of the most important PowerPoint presentation tips to follow when designing your slides. Keep in mind that less is more (effective.) A cluttered slide is distracting. It causes confusion for an audience: Which part of the slide should I focus on? Should I read the slide or pay attention to the presenter?

A simple, visually appealing slide will engage your audience, keeping them on track with your main points. Here’s an example of a simple slide that serves its purpose perfectly:

Minimalist slide templates like Nook can help you resist the urge to clutter your slides.

9. Limit Words on Your Slides

Piggybacking on the last point, less is more effective. If possible, avoid bullets altogether. Otherwise cut them to just a few simple words. The audience should be listening, not reading.

10. Use High-Quality Photos and Graphics

One of the most important tips for quality PowerPoint presentations is to use high-quality photos and graphics.

Earlier in this tutorial, you saw Envato Elements, an all-you-can-download service with PPT tips inside of templates. Those pre-built designs are a beginner’s best friend. They’re even better when paired with Elements’ unlimited library of stock photos .

People are more likely to take you seriously if your presentation is visually appealing. Users view attractive design as more usable. Similarly, they’ll view a more attractive PowerPoint as more effective.

11. Use Accurate and Relevant Charts and Graphs

Charts and graphs can also be distracting if they’re not used right. Make sure your information design is simple and clean so that the audience doesn’t spend the entire time trying to decipher what your X axis says. Learn more about PPT data presentation .

12. Use High-Quality, Fresh Templates

Have you seen the old PowerPoint template that looks like worn paper and uses ink splashes? Yeah, so has your audience. Templates can be distracting if they’re too basic or if the design feels dated. You need one with great design options.

Costs are always a concern. But when you use Envato Elements, you’ve got everything you need to create a great PowerPoint presentation . That’s thanks to the incredible all-you-can-download subscription package.

The best PowerPoint tips and tricks can hardly compare to the value of using a template while building your presentation.

On Envato Elements, there are thousands of PowerPoint design templates that are ready to use. Instead of designing a presentation from scratch, start with a template! Just add your specifics to the placeholders.

Templates like Galaxi are impressively designed and waiting for your slide specifics.

The best PowerPoint design tips save you time. And there’s no tip more powerful than this one: use a pre-built template . It helps you master how to present a PowerPoint without spending all your time in the app.

13. Choose Appropriate Fonts

Fonts are an important part of engaging your audience. Fonts and typography choices have a subconscious effect on viewers. They can characterize your company’s presentation and brand either positively or negatively. Make sure that you’re choosing fonts that are professional and modern.

14. Choose Color Well

Like font choice, colors cause specific subconscious reactions from viewers. Choosing an outdated color combination for your presentation will render it ineffective.

Below is an example of the Popsicle PowerPoint template , which has a modern presentation color choice:

The Popsicle PowerPoint template highlights how harmonized color palettes can create beautiful slides.

15. Clean + Simple Formatting Makes All the Difference!

We’ve got a full tutorial on how to make a good presentation slide . Give it a read through and review the accompanying video. Just remember, less is more. The focus is you and your message , not your slides.

16. Make Sure All Objects Are Aligned

A simple way to create a well-designed presentation is to make sure all items on a slide are intentionally aligned. To do this, hold down Shift and select all the objects you want to include. Then choose Arrange in the options bar and apply Alignment Type .

17. Limit Punctuation

This isn’t the place for exclamation points. Emphasize your points (while speaking). Don’t enlist punctuation to do this for you. (Leave these at home!!!)

18. Avoid Over-Formatting Your Points

This PowerPoint presentation tip is simple. There’s no need to have every word of every bullet point capitalized, or to have all your bullet points in title case. If possible, drop bullets altogether. Again, the simpler, the better!

Limit your text formatting, including reducing the use of bullets, underline, and other effects. Compare the before example on the left to the revised version on the right.

19. Combine Information With Graphics in PowerPoint

One of the most powerful presentation skills for PPT is using infographics. With the right type of visuals, slides come to life and reduce the text in favor of graphics.

Infographics help combine information with graphics. It’s easier to explain complex ideas when you use visual formats that are intuitive.

Practice Presentation Tips: Rehearse, Rehearse, Rehearse!

Delivery is probably more important than the actual content. Here’s how to become more aware of your own unique ticks, and how to present like a polished pro:

20. I’ll Say It Again, Rehearse!

Just do it. Again and again. Experiment with pauses, gestures, and body language. Practice around one hour for every minute of your speech.

21. Practice With a Timer

Consistency is key to an effective PowerPoint presentation. The timing should be similar (ideally the same) each time you rehearse. This one will especially pay off when it’s time to present in front of your audience.

22. Slow It Down

Many of the best speakers today intentionally speak slowly. You’ll have the chance to emphasize, appear more thoughtful, and make your information easier to digest.

23. Pause More Often

Like the prior tip, pausing more often allows your main points to be emphasized and gives time for information to sink in. You need to let key points breathe a little before rushing into the next section.

24. Record Yourself

Use your phone’s voice recorder. Assess and critique yourself. Consider:

• Are your pauses too short or too long?
• Are you speaking slowly enough? Too slow?
• When you’re nervous, does your voice get high like the mice in Cinderella?

It’s always weird to hear your own voice recorded; don’t stress it. Use this as a time to adjust.

25. Choose Three Focal Points in the Room

If you stare at the same spot (or even creepier, the same person) the entire time, your presentation will be ineffective (and awkward.) People will be distracted by you, wondering what you’re staring at.

Try this: pick three points in the room (typically: left, center, right). Take time to direct your delivery toward each physical focal point in the room. Also, focus on the center when making your primary points.

26. Vary Your Sentence Length

This makes you sound more interesting, and it’s easier for your audience to follow. Think short and punchy. Or go long and complex for dramatic effect.

27. Modulate!

Don’t speak in monotone for your whole presentation. Be conscious of raising and lowering your voice tone. Otherwise, people will tune you out, and you’ll come across like the teacher in Charlie Brown.

28. Practice in Front of a Mirror

What you look like is as important as how you sound. Pretend you’re having a normal conversation, and allow your hands to move with your speech to emphasize your points. Just don’t get carried away! (I’m thinking Brene Brown or President Obama , not your Aunt Jamie after a few gin and tonics.)

29. Use “Present Mode” When Rehearsing

When you finally are ready to hit the Present button in PowerPoint, make sure you use the Present Mode option. This allows you (and only you) to view extra notes about each slide—just in case you forget something!

30. Practice With New Audiences

If possible, try doing a few real live test runs as a webinar or even at a local Toastmasters organization to get some feedback from a live audience.

31. Engage the Audience by Asking Questions

There’s no reason that a presentation should be one-sided. Why not invert the format and ask your audience a question?

To learn how to create a slide that kicks off a Q&A, use this article . These PowerPoint design tips help you create an engaging and exciting discussion.

Helpful Tips to Step Up and Deliver Come Presentation Time

When the actual day arrives, there are only a few last PowerPoint presentation tips and guidelines to keep in mind:

32. Take a Deep Breath

Deep breathing is proven to relieve stress. It’s simple, and it’ll help you remain calm and in the moment, even up to the last minute before starting.

33. Lighten Up Your Mood

Tell yourself a joke or watch a funny video clip. Do this before the presentation, of course. Research concludes that happy people are more productive. More productive is more focused and able to perform better.

34. Remind Yourself to Take It Slow

When we’re stressed or nervous (or both), we tend to speak faster. Consciously, take yet another deep breath and remind yourself to take it slow!

35. Read the Room

Every presentation room has a temperature. It’s your job as a speaker to gauge it and tailor your presentation to it.

Here’s a great example. Layoffs are coming at a company, and you’re asked to speak to an audience. Even if the audience isn’t personally affected by the actions, you’ve got to consider the morale of the workforce.

Skilled speakers have a knack for reading the energy of the room and adjusting their presentation on the fly.

The last thing that group will want to hear is how strong the economy is and why the company is the best place to work. That doesn’t mean that you’ve got to align to their uncertainty, but don’t go too far against the grain while presenting.

Robert Kennedy III is a master of bringing energy and aligning a speech to the audience. Here’s his advice for adjusting:

“It can be hard to wake up a “dead” crowd but go for it. Most of all, don’t take their energy personally. Focus on serving them with every bit of your fiber then leave empty.”

36. Fake It ‘Til You Make It!

Go forward with confidence. If you act confident, you’ll start to feel more confident. Move slowly with grace, speak clearly, smile, wear something nice. You’ll appear confident to all attendees (no matter how you feel internally).

PowerPoint Presentation Tips and Tricks to Help Avoid Mistakes (What Not to Do)

Most importantly, focus on what you can do to make your presentation better. There are a few important things not to do that we’ve got to address. Here are a handful of PowerPoint presentation tips and tricks to help you avoid missteps.

37. Stop With the Sound Effects

Sound effects are distracting and outdated. In most cases, avoid them. Add audio or music to your presentation to inject interest or highlight an important point, but it’s something to take extra care with. If you insert audio, then make sure your use really connects with your audience and has a fresh approach. Otherwise, it’s best to leave it out.

38. Don’t Use Flashy Slide Transitions

Again, this is distracting and outdated. Use transitions and subtle animations in your PowerPoint presentation. But you need to take care and do it right .

39. Beware of Clip Art

This PowerPoint presentation tip shouldn’t even have to be said. But please, please don’t use clip art. Use professional graphics instead.

40. Don’t Be Afraid to Be Afraid

The fear of public speaking is a real one. Many beginners think that if they’re feeling nervous that a presentation won’t go well or succeed. That might lead them to cancel the presentation.

Here’s a tip from expert Sandra Zimmer, who leads The Self-Expression Center on conquering your fears before you take the stage:

“Get out of your head and into your body. I do this through a grounding exercise that really works to calm nerves and bring you present in the moment.”

If you think that public speaking fears aren’t normal, you might never give your award-winning presentation. So don’t be afraid to be afraid, and acknowledge it’s part of the process!

41. Don’t Read Directly During Your PowerPoint Presentation

If you spend your entire presentation looking at the screen or your note cards, you’re sure to lose your audience’s attention. They’ll disengage from what you’re saying, and your presentation will fall flat.

Reading from your paper or screen also makes it look like you’re not prepared. Many people do it, but no one should. As a general rule, only present something you know well and have, at least mostly, memorized the main points of.

42. Don’t Miss Out on PowerPoint Customizations

Many new PowerPoint users often make significant mistakes when using Envato Elements designs.

The best way to see how to make a good presentation PPT is to start with designs from others. That means using a template, but that doesn’t mean you can’t customize them!

Don’t forget that PowerPoint templates are infinitely customizable. Think of them as guides with built-in presentation design tips.

To see more presentation tips that show you what not to do, make sure to check out our guide .

Work in PowerPoint More Effectively (Tips & Tricks to Level Up Your PPT Skills)

These PowerPoint tips will help you get the most out of the application to level up your next presentation. Let’s dive in.

43. Use the Visual Guides

When you’re designing your next PowerPoint presentation, it helps to create a sense of visual rhythm. Slides that have objects aligned and centered are more likely to resonate with an audience.

44. Use a Few Animations (Tastefully)

Animations in effective PowerPoint presentations are a slippery slope. We’ve all sat through presentations where there were so many objects in motion that it was easy to lose focus on the key ideas in the presentation.

But that’s why animations get an unfairly bad reputation. Use animations to create motion and hold an audience’s attention. Use them sparingly and on key elements on your slide, and you’ll capture that attention properly.

45. Stage Key Content With Animations

You just learned that animations should avoid being distracting. But there’s an important principle to using animations properly. It’s called staging content.

Staging content means that the content appears step by step. There’s nothing worse than overwhelming an audience with all your content at once. But when you stage content, bring it on step by step.

Take it from presentation pro Suzannah Baum :

“If you’re sharing a slide with lots of different points on it, using the animation to reveal those points one at a time is a way to keep the presenter’s content flowing smoothly.”

For more animation presentation tips and tricks, follow our guide .

46. Add a Video to Your PowerPoint

When you’re sharing a big idea in your presentation, it helps to share your perspective from a few different angles. Adding a video to supplement your content can do just that. Luckily, it’s easy to add and embed a YouTube video in your next PowerPoint presentation.

47. Add Charts & Graphs

Charts and graphs can help you tell stories with data. It’s easy for an audience to zone out when you throw a big data table or set of statistics at them.

instead, convert those to charts and graphs. Try out our tutorial to learn how to edit those graphs.

48. Build Your Own Infographics With SmartArt

Earlier in this tutorial, we gave you one of my favorite PowerPoint design tips: use infographic templates.

Here’s another. One of my favorite PowerPoint features is SmartArt, which allows you to build infographics right inside the app.

You don’t have to use another graphic design app like Photoshop or Illustrator to add visuals. Instead, try out SmartArt to help you build graphics that are easy to update.

49. Use Presenter View

Remember that when you use the PowerPoint, you’ re the presentation. The slides are just there to reinforce what you’ve got to say and support your speaking points.

That’s why I always recommend using Presenter view. More often than not, you’re going to have several displays. Presenter view shows your content on your screen, while your presentation is displayed on another screen.

50. Track Your PowerPoint Changes

One of my favorite PowerPoint design tips is to collaborate. Those who know you best will suggest compelling changes that are sure to help you succeed.

As you start collaborating on your presentation, it helps to keep track of proposed and included PowerPoint changes. Use this article to track changes made by others.

10 More Advanced PowerPoint Tips & Tricks

Really need to wow an audience with a good PowerPoint presentation? Give these tips a try to make an unforgettable impression:

51. Engage With an Interactive Quiz

A good PowerPoint presentation gets your audience involved. One of the best PowerPoint tricks is to do that with a quiz. By engaging audiences, a quiz makes your slides memorable.

By adding trivia, you’ll see how to present a PowerPoint in a way that people will love. Channel your inner game-show host today. MIDTEST is a  good PowerPoint presentation  with quiz slides.

52. Illustrate With Custom Image Masks

One of the top PowerPoint tips is to illustrate your slides. But you can go beyond simple, rectangular images on each slide.

The Burte template is full of  PowerPoint tricks , including custom image masks. Image masks shape photos into unique works of art. And thanks to premium templates, you can style photos just like this. Masks overlay your photos onto geometric shapes, instantly elevating your style.

53. Print Handouts With Extra Notes

Wonder how to give a good presentation PPT that audiences will remember? Give them a piece of it to take home.

PowerPoint makes it easy to print handouts with room for notes on the page. This way, audiences can keep copies of your slides, along with their own notes. This is the perfect way to ensure everyone engages with and retains your content.

54. Make Bulk Edits With Master Slides

When you think about how to present a PowerPoint, consider your branding. That means keeping your logo front and center in the eyes of an audience. But if you’re working with a lengthy slide deck, this could seem daunting.

That’s where master slides come in. They’re common in premium layouts, and they’re a leading example of presentation skills for PPT. Master slides let you make bulk edits fast.

55. Shrink File Sizes for Sharing

Many of the top presentation tips involve making your slides more accessible. Often, that involves sharing them with audiences online.

You’ll often find that email clients and cloud services limit the size of files that you share. This can be a problem with large PPT slide decks. But there are a few quick steps you can take to reduce PPT file size. Cut graphics, scale down photos, and more.

56. Map Processes With Flowcharts

As you consider how to do a good PowerPoint presentation, think of ease of understanding. After all, you’re trying to explain something to your audience.

The  Flowcharts in Infographics  template seamlessly illustrates ideas and processes. A flowchart maps out a process in a visual way. Instead of resorting to endless narration, try a quick illustration like this. It saves you time and effort, and your audience is sure to thank you.

57. Use Brand-Specific Colors

Using presentation skills for PPT helps form an association between your message and branding. There’s no better way to do that than with your brand colors.

PowerPoint makes it easy to change color themes, adding your brand colors and logo to each slide. This is one of the top PowerPoint tricks for marketing presentations.

58. Build Social Media Posts in PPT

A good PowerPoint presentation doesn’t have to be shared through a projector. Use the app and templates to build amazing illustrations to use anywhere.

A template like Soffee helps you learn how to present a PowerPoint easily with a pre-built design.

Try using PowerPoint to create social media posts. It helps you engage with your audience, with no need to design custom layouts from scratch.

59. Be Industry-Specific

One of the top presentation tips in 2024 is to be industry-specific. That means avoiding generic layouts and choosing something more customized.

This offers two key advantages. First, you save time by having layouts built for you. Second, you gain design inspiration for your specific topic. Themed templates are truly the best of both worlds.

The Medical and Health template is a good PowerPoint presentation with a set theme.

60. Design for Online (Virtual) Sharing

Last but not least in our list of PowerPoint tips comes virtual presenting. More and more often, slides will be shared with online audiences around the globe.

Why not design your slides for that very purpose? And then learn how to share flawlessly with a global team? It’s one of the top presentation tips for 2024. Embrace it today.

More Great PowerPoint Tutorial Resources

We’ve built a resource for Microsoft PowerPoint that you’re sure to want to try. It includes countless PowerPoint tips and tricks. It’s called How to Use PowerPoint (Ultimate Tutorial Guide) and has all the PowerPoint design tips you need.

Discover More Top PowerPoint Template Designs From Envato Elements for 2024

You’ve just seen our favorite powerful PowerPoint presentation tips and guidelines to help you improve your speaking. We’ve also mentioned Envato Elements, an incredible all-you-can-download source for top PowerPoint designs .

Here are five of the best PowerPoint templates that you can use to create your best presentation yet:

1. Galaxi PowerPoint Template

Blast off to success with the help of this PowerPoint template! Think of the pre-built slide designs as pro PowerPoint design tips. They’re built by professional graphic designers. All the popular and modern slide styles that are perfect for your next presentation. Use Galaxi’s five styles and 30 designs to create a great presentation.

2. Masmax PowerPoint Template

We selected templates for this article that match the PowerPoint tips and tricks provided. Masmax fits the bill perfectly across its 234 unique slide designs. These slide designs are sure to align with the latest in design expectations.

3. STYLE Multipurpose PowerPoint Template V50

Style is subjective, but we can all agree that this template is stunning! The light and airy slide designs are built with fashion-focused designs in mind. But that doesn’t mean that it’s not perfect for most presentations. When learning to present a PowerPoint, remember that templates can be customized to suit your purpose.

4. Peachme Creative PowerPoint Template

Peachme has image-focused slides with splashy designs. The slides are colorful and perfect for a modern presentation. Don’t worry about remembering all the PowerPoint design tips because they’re included in the pre-built slides. Use Peachme’s designs for your presentation today.

5. Buizi Office Building Rent PowerPoint Template

Buizi markets itself as a real estate focused template. It’s ideal for that purpose because of the minimal, image-focused slide designs. But that also makes it a perfect choice for presentations in many fields.

We’ve just scratched the surface of PowerPoint design tips with these five options. Here are many more, bundled inside of the best roundups on Envato Tuts+:

How to Build a Good PowerPoint Presentation Quickly (In 2024)

You’ve already seen effective presentation skills PPT techniques. But you may be wondering exactly how to do a good PowerPoint presentation. It only takes a few clicks. Let’s learn how in just five steps.

For this mini-tutorial, we’ll use the Enjoy PowerPoint Template from Envato Elements. You’ll see that it’s a beautiful template that helps you learn how to present a PowerPoint by giving you every object and layout you need.

Let’s get started:

1. Choose Your Slides

As you can see, a template like Enjoy has dozens of unique slides inside. The key to how to give a good presentation PPT is to choose only the slides that you need.

One of the best PowerPoint tricks is to start by selecting slides you wish to use from your template.

In PowerPoint, scroll through the sidebar on the left to view different slide layouts. Right-click and choose Delete to remove unwanted designs. Plus, you can click and drag slide thumbnails to reorder them in the deck.

2. Add Text

Consider how to do a good PowerPoint presentation without investing a ton of time. That’s where premium templates come in.

One of our top presentation tips when working with a PPT is to lean on the pre-built text boxes for your content.

To add custom text, simply click and select the contents of any text box on your slide. Then, type in your own words. Repeat as needed throughout your slide deck.

3. Customize Fonts

With text selected, it’s easy to customize fonts on each slide. Find the Font section on PowerPoint’s Home tab. From there, you’ve got a variety of dropdown options.

Another of our top tips for presentation tricks is to use a custom font setting in your template.

Click to change the font, font size, and more. You can also use the buttons on the left to add bolds, italics, and more.

Need more custom font styles? As an Envato Elements subscriber, you’ve got instant access to thousands of custom fonts . Use them in your presentation with ease.

4. Insert Images

Slides like this one contain an image placeholder. That’s another advantage found only with premium templates. These make adding images a breeze.

Add images to your PPTX template for more visually interesting slides.

To get started, find an image file stored on your computer. Then, drag and drop it over the placeholder. PowerPoint will import it, sized and scaled for a perfect fit.

5. Change Colors

One of the top effective presentation skills is changing shape colors. This helps you control the look and feel of each slide.

With a shape selected, find the Shape Format tab on PowerPoint’s ribbon. Then, click on the Shape Fill dropdown. You’ll see a color chooser menu appear. Click on any thumbnail to apply it to the shape or browse through the Gradient and Texture options.

Start Putting These PowerPoint Presentation Tips & Tricks Into Use Today!

Learning to write, design, and present a PowerPoint presentation is an invaluable skill, no matter where you use it. If you’re a good communicator of important messages, you’ll never go hungry.

Luckily, improving PowerPoint presentations isn’t as hard as it seems. Follow these tips for PowerPoint presentations to design and deliver with greater confidence.

Remember: Less is more (effective) . Use PowerPoint presentation templates for better design and more effective visual impact. And you can customize a PPT template quickly , with the right workflow.

Related Articles

How-To Geek

How i use copilot to easily create powerpoint presentations in minutes.

Your changes have been saved

Email Is sent

Please verify your email address.

You’ve reached your account maximum for followed topics.

Quick Links

You first need to add copilot to powerpoint, generate an entire presentation with a single prompt, asking copilot to add a slide, add images to the presentation using copilot, organizing the presentation with copilot’s help, key takeaways.

• Ensure you have a Microsoft 365 and Copilot Pro subscription in order to use Copilot in PowerPoint.
• You can generate a full presentation, with text, images, and summaries, by providing a single prompt to Copilot.
• You can also request Copilot to add slides and images or organize the presentation.

When I have trouble creating a presentation in PowerPoint, I use something in my creative arsenal that can help me do it in minutes: Copilot. Here's how I use it to generate entire presentations, add slides, and more.

To use Copilot in PowerPoint, you need two subscriptions. Since PowerPoint is a Microsoft 365 app , you’ll need a Microsoft 365 subscription, which costs $6.99 a month. You will also need a Copilot Pro subscription, which costs $20 per month.

After purchasing those subscriptions, you should see the "Copilot" button on the ribbon of the Home tab in PowerPoint.

If you don't see Copilot, you'll need to add it by updating your Microsoft 365 license. To do that, head to File > Account and click “Update License” in the Product Information section.

Then, follow the instructions to sign in to your Microsoft account. Ensure it’s the one with the Microsoft 365 and Copilot Pro subscriptions. Then, close PowerPoint and relaunch it—you should be able to see Copilot now.

If you want to create an entire presentation, you have to tell Copilot the topic of the presentation, and it will generate it for you. To do that, use the following syntax: Create a presentation about [Topic] . In the prompt, replace Topic with what you want Copilot to write about.

If you want it to include additional slides based on the topic, you can expand your prompt further. You could, for instance, add the following to the prompt: Include slides about [Sub Topic 1], [Sub Topic 2], [Sub Topic 3] . Replace Sub Topic 1, Sub Topic 2, Sub Topic 3, and so on in the prompt with the topics of the slides.

For instance, I created a presentation about doomscrolling using this prompt: Create a presentation about doomscrolling. Include slides about what it is, its origin, why we do it, and how to stop it .

Once you press Enter on your keyboard, Copilot will generate an entire presentation, complete with text and images. Also, it will include notes at the bottom of each slide, giving you a quick summary. Take time to go through it and correct any errors—AI-generated content might consist of incorrect information.

One thing to remember is that Copilot might not have created the exact number of slides you stated. It might add more or miss some (it's not perfect).

After Copilot creates the presentation, you can ask it to add more slides. The syntax is: Add a slide about [Topic] . In a presentation about the steps to mindful meditation, I wanted to add a slide about remembering to notice thoughts. I typed the following in Copilot: Add a slide about noticing thoughts without passing judgment .

If I wanted to animate a slide, I would select it from the list of slides on the left panel, and type: Animate this slide . I can even add an agenda to the entire presentation by typing: Add an agenda slide .

You can add images to a slide by using the following syntax: Add an image of [Image Description] . Ensure it's short and sweet while being adequately descriptive so that Copilot understands what you mean.

I decided to include an image of a dog doing yoga in one of my presentations by typing: Add an image of a dog doing yoga .

If you feel the presentation could be better organized, Copilot can help. It can suggest the best structure based on what it knows about it. To do that, type the following in Copilot: Organize this presentation .

After you see Copilot's suggested slide order for the presentation, it's up to you to accept or reject the changes.

Remember, you can use Copilot in other Microsoft 365 apps as well. You can, for example, use it to write documents in Word or do calculations in Excel in minutes. Being able to use it in Microsoft 365 apps like this can significantly boost your productivity.

• Microsoft PowerPoint
• Microsoft 365

• What Are HIV and AIDS?
• How Is HIV Transmitted?
• Who Is at Risk for HIV?
• Symptoms of HIV
• U.S. Statistics
• Impact on Racial and Ethnic Minorities
• Global Statistics
• HIV and AIDS Timeline
• In Memoriam
• Supporting Someone Living with HIV
• Standing Up to Stigma
• Getting Involved
• HIV Treatment as Prevention
• Pre-exposure Prophylaxis (PrEP)
• Post-exposure Prophylaxis (PEP)
• Preventing Sexual Transmission of HIV
• Alcohol and HIV Risk
• Substance Use and HIV Risk
• Preventing Perinatal Transmission of HIV
• HIV Vaccines
• Long-acting HIV Prevention Tools
• Microbicides
• Who Should Get Tested?
• HIV Testing Locations
• HIV Testing Overview
• Understanding Your HIV Test Results
• Living with HIV
• Talking About Your HIV Status
• Locate an HIV Care Provider
• Types of Providers
• Take Charge of Your Care
• What to Expect at Your First HIV Care Visit
• Making Care Work for You
• Seeing Your Health Care Provider
• HIV Lab Tests and Results
• Returning to Care
• HIV Treatment Overview
• Viral Suppression and Undetectable Viral Load
• Taking Your HIV Medicine as Prescribed
• Tips on Taking Your HIV Medicine as Prescribed
• Paying for HIV Care and Treatment
• Other Health Issues of Special Concern for People Living with HIV
• Alcohol and Drug Use
• Coronavirus (COVID-19) and People with HIV
• Hepatitis B & C
• Vaccines and People with HIV
• Flu and People with HIV
• Mental Health
• Mpox and People with HIV
• Opportunistic Infections
• Sexually Transmitted Infections
• Syphilis and People with HIV
• HIV and Women's Health Issues
• Aging with HIV
• Emergencies and Disasters and HIV
• Employment and Health
• Exercise and Physical Activity
• Nutrition and People with HIV
• Housing and Health
• Traveling Outside the U.S.
• Civil Rights
• Workplace Rights
• Limits on Confidentiality

National HIV/AIDS Strategy (2022-2025)

• Implementing the National HIV/AIDS Strategy
• Prior National HIV/AIDS Strategies (2010-2021)
• Key Strategies
• Priority Jurisdictions
• HHS Agencies Involved
• Learn More About EHE
• Ready, Set, PrEP
• Ready, Set, PrEP Pharmacies
• Ready, Set, PrEP Resources
• AHEAD: America’s HIV Epidemic Analysis Dashboard
• HIV Prevention Activities
• HIV Testing Activities
• HIV Care and Treatment Activities
• HIV Research Activities
• Activities Combating HIV Stigma and Discrimination
• The Affordable Care Act and HIV/AIDS
• HIV Care Continuum
• Syringe Services Programs
• Finding Federal Funding for HIV Programs
• Fund Activities
• The Fund in Action
• About PACHA
• Members & Staff
• Subcommittees
• Prior PACHA Meetings and Recommendations
• I Am a Work of Art Campaign
• Awareness Campaigns
• Global HIV/AIDS Overview
• U.S. Government Global HIV/AIDS Activities
• U.S. Government Global-Domestic Bidirectional HIV Work
• Global HIV/AIDS Organizations
• National Black HIV/AIDS Awareness Day February 7
• HIV Is Not A Crime Awareness Day February 28
• National Women and Girls HIV/AIDS Awareness Day March 10
• National Native HIV/AIDS Awareness Day March 20
• National Youth HIV & AIDS Awareness Day April 10
• HIV Vaccine Awareness Day May 18
• National Asian & Pacific Islander HIV/AIDS Awareness Day May 19
• HIV Long-Term Survivors Awareness Day June 5
• National HIV Testing Day June 27
• Zero HIV Stigma July 21
• Southern HIV/AIDS Awareness Day August 20
• National Faith HIV/AIDS Awareness Day August 27
• National African Immigrant and Refugee HIV/AIDS and Hepatitis Awareness Day September 9
• National HIV/AIDS and Aging Awareness Day September 18
• National Gay Men's HIV/AIDS Awareness Day September 27
• National Latinx AIDS Awareness Day October 15
• World AIDS Day December 1
• Event Planning Guide
• U.S. Conference on HIV/AIDS (USCHA)
• National Ryan White Conference on HIV Care & Treatment
• AIDS 2020 (23rd International AIDS Conference Virtual)

Want to stay abreast of changes in prevention, care, treatment or research or other public health arenas that affect our collective response to the HIV epidemic? Or are you new to this field?

HIV.gov curates learning opportunities for you, and the people you serve and collaborate with.

Stay up to date with the webinars, Twitter chats, conferences and more in this section.

• Share on Facebook
• Share on Twitter
• Share on LinkedIn
• Share on Email

New: NHAS 2023 Interim Action Report

The White House published the National HIV/AIDS Strategy 2023 Interim Action Report  (PDF 387 KB) on December 1, 2023, highlighting actions taken by federal partners during FY22 and FY23 to move the nation closer to reaching the four goals laid out in the Strategy.

What Is the National HIV/AIDS Strategy?

The National HIV/AIDS Strategy for the United States (2022–2025 ) was published in December 2021 and provides stakeholders across the nation with a roadmap to accelerate efforts to end the HIV epidemic in the country by 2030.

The Strategy reflects President Biden’s commitment to re-energize and strengthen a whole-of-society response to the epidemic while supporting people with HIV and reducing HIV-associated morbidity and mortality.

The White House’s Office of National AIDS Policy (ONAP), part of the Domestic Policy Council, facilitated development of and published the Strategy, which builds on the 2021 HIV National Strategic Plan and the two prior National HIV/AIDS Strategies (2010, 2015).

Key Elements of the National HIV/AIDS Strategy

The Strategy articulates a clear vision to guide the nation’s response to HIV:

The Strategy sets bold targets for ending the HIV epidemic in the United States by 2030, including a 75% reduction in new HIV infections by 2025 and a 90% reduction by 2030. To guide the nation toward realizing the vision, the Strategy focuses on four goals:

• Prevent new HIV infections.
• Improve HIV-related health outcomes of people with HIV.
• Reduce HIV-related disparities and health inequities.
• Achieve integrated, coordinated efforts that address the HIV epidemic among all partners and stakeholders.

Objectives & Strategies

For stakeholders across the nation, the Strategy details 21 objectives and 78 strategies for federal and nonfederal stakeholders to implement to achieve the goals.

Priority Populations

The Strategy d esignates five priority populations disproportionately impacted by HIV so that federal agencies and other stakeholders can focus efforts and resources to achieve the greatest impact. The populations are:

• gay, bisexual, and other men who have sex with men, in particular Black, Latino, and American Indian/Alaska Native men;
• Black women;
• transgender women;
• youth aged 13–24 years; and
• people who inject drugs.

Indicators of Progress

To monitor national progress toward its goals, the Strategy

• identifies eight core indicators,
• establishes a disparity indicator stratified by the priority populations to measure progress toward reducing significant HIV-related disparities, and
• incorporates five indicators focused on quality of life among people with HIV.

Read a factsheet “National HIV/AIDS Strategy: What You Need to Know.”

View the NHAS At-a-Glance that summarizes the goals, objectives, strategies , and indicators of progress.

How Was the Strategy Developed?

ONAP developed the current Strategy in the latter half of 2021, informed by significant input from community stakeholders, including people living with HIV, and supported by federal partners from nine federal Departments whose programs, policies, services, or activities contribute to our national response to HIV. The Strategy builds on the progress achieved and lessons learned from the prior national strategies and seeks to leverage new tools and opportunities to address the challenges that remain.

Learn about the prior National HIV/AIDS Strategies .

Visit HIV.gov’s page about how the NHAS is being implemented.

• Read blog posts related to the NHAS .
• View a video of the NHAS release at the 2021 White House World AIDS Day event Exit Disclaimer .
• Read remarks by President Biden to Commemorate 2021 World AIDS Day, Launch the National HIV/AIDS Strategy, and Kick Off the Global Fund Replenishment Process .
• Read HHS Secretary Becerra’s remarks at the 2021 White House World AIDS Day event where the NHAS was released.
• Download a White House fact sheet: The Biden-⁠Harris Administration Marks World AIDS Day 2021 With Renewed Commitments to Ending the HIV/AIDS Epidemic by 2030 .
• Read a roundup of news coverage highlights about President Biden commemorating World AIDS Day and launching the new National HIV/AIDS Strategy .
• View HIV.gov’s webinar on how to use the National HIV/AIDS Strategy .

Related HIV.gov Blogs

• NHAS National HIV AIDS Strategy

This is a potential security issue, you are being redirected to https://csrc.nist.gov .

You have JavaScript disabled. This site requires JavaScript to be enabled for complete site functionality.

An official website of the United States government

Here’s how you know

Official websites use .gov A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS A lock ( Lock Locked padlock icon ) or https:// means you’ve safely connected to the .gov website. Share sensitive information only on official, secure websites.

Cryptographic Corollaries of the Classification of Finite Simple Groups

Description.

Abstract. The Semidirect Discrete Logarithm Problem (SDLP) is a potentially appealing generalisation of the standard Discrete Logarithm Problem (DLP) arising from a more involved algebraic structure. It was hoped that there would be a gap between the quantum complexity of SDLP and that of DLP, allowing for development of post-quantum schemes based on SDLP.Unfortunately, in the case of SDLP with respect to finite groups, this turns out not to be the case. In this talk we present two powerful tools allowing us to reach this conclusion: the first is a method of decomposition of a generic instance of SDLP into several instances of SDLP in a finite simple group; the second is a survey of SDLP in each finite simple group, aided by the celebrated classification theorem.

Based on joint work with Ryann Cartor, Nadia Heninger, David Jao, Laura Maddison, Edoardo Persichetti, Angela Robinson, Daniel Smith-Tone, Rainer Steinwandt.

Suggested readings: ia.cr/2022/1165 , ia.cr/2023/1953 , ia.cr/2024/905

Presented at

Parent project, related topics.

Security and Privacy: cryptography